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ABSTRACT
Isoflavones are biologically active plant chemicals (phytoestrogens) which are ordinarily
present in human diets. There is considerable research interest in their potential to
prevent or treat several chronic diseases. Biomarkers can demonstrate compliance during
dietary interventions and validate associations between intake of isoflavones and health
outcomes.
The objectives of this study were to validate 24-hour urine collections, timed spot urine
samples and timed plasma samples as biomarkers of isoflavone intake up to 165mg/day.
Healthy volunteers (20 women and 11 men) consumed 55mg/d, 110mg/d or 165mg/d soy
isoflavones or placebo for seven consecutive days in a randomised, double-blind, cross-
over study. Timed blood samples, timed spot urine samples (taken in the afternoon, 5-7
hours after consuming the isoflavone supplement) and 24-hour urines were obtained at
baseline and during each intervention. Isoflavone content of the samples was assayed by
liquid chromatography and mass spectrometry. 24-hour urines were validated by
percentage PABA recovery.
The relationship between daily isoflavone intake and 24-hour urinary isoflavone
excretion was:
y = 6.63132x0.7421 ≡ x = (y ÷ 6.63132)1.3475
where y = isoflavone excretion in μg/24h and x = isoflavone intake in μg/24h
r2 = 0.86; p < 0.001; n = 109 samples from 31 volunteers
The relationship between daily isoflavone intake and plasma isoflavone concentration
was:
y = (3.3543x10-3)x0.4889 ≡ x = (y ÷ 3.3543x10-3)2.0454
where y = plasma isoflavone in μg/ml and x = isoflavone intake in μg/24h
r2 = 0.61; p < 0.001; n = 100 samples from 30 volunteers
The relationship between daily isoflavone intake and spot urine isoflavone concentration
was:
y = (2.0324x10-3)x0.8009 ≡ x = (y ÷ 2.0324x10-3)1.2486
where y = isoflavone excretion in μg/ml and x = isoflavone intake in μg/24h
r2 = 0.69; p < 0.001; n = 143 samples from 31 volunteers
It was concluded that 24-hour urine collections, timed plasma samples and timed spot
urine samples are valid biomarkers of isoflavone intakes up to 165mg/day.
A curvilinear relationship was defined between a) isoflavone dose and bioavailability in
plasma and b) isoflavone dose and 24-hour urinary excretion.
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INTRODUCTION
An overview of the field of phytoestrogen research will be presented before
elaborating the chemical classification and dietary sources of isoflavones and the
pharmacology and pharmacokinetics of these compounds. The rationale for this study
will be presented in the context of current research into isoflavones in humans.
BACKGROUND
Plants contain a diverse array of chemicals which can have a substantial impact on
human health, particularly if consumed over the course of a lifetime. Food
phytochemicals in particular have attracted a great deal of interest in recent years in
light of their potential to reduce the risk of chronic diseases, or improve the prognosis
once the disease process has initiated. Indeed, it has been suggested that the major
influence on the risk for Western diseases relates to an inadequate intake of plant
products rather than to any other dietary factor (Griffiths et al., 1996).
Phytoestrogens (PE) are among the most investigated food phytochemicals. As
defined by the Commission on Toxicology (COT) Working Group, PE are plant
substances and their human metabolites that induce biological responses and can
mimic or modulate the actions of endogenous oestrogens, usually by binding to
oestrogen receptors (COT, 2003b).
These responses include influences on the production, metabolism and cellular
activity of sex steroids; influences on growth factors; on protein synthesis; on
intracellular enzymes and signalling cascades; on free radical reactions and on the
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proliferation, differentiation and metastasis of malignant cells (Adlercreutz & Mazur,
1997).
PE are present in a wide range of foods and medicinal plants and include isoflavones
in soy foods and red clover; prenyl flavonoids in hops and beer; coumestans in alfalfa;
lignans in linseeds, whole grains and berries (Cos et al., 2003); resveratrol in nuts,
grapes and red wine (Kris-Etherton et al., 2002); glabridin (Tamir et al., 2000) and
licochalcone-A (Rafi et al., 2000) from liquorice; ginsenosides in ginseng (Chan et
al., 2002) and others (Zava et al., 1998). In plants, the PE glycosides genistin and
daidzin are among the phytoalexins which protect the plant against pathogens, so their
concentration in the plant depends upon the presence or absence of pathogenic attack,
as well as on the season and variety of the plant (Dixon & Ferreira, 2002).
There has been increasing interest in PE since the mid-1940s, when fertility disorders
consistent with an anti-oestrogenic effect were observed in ewes grazing on
subterranean clover (Trifolium subterraneum) which is rich in isoflavones (Bennetts
et al., 1946). The ewes’ intestinal microflora metabolised formononetin in the clover
to equol, a potent PE.
After the chance discovery of equol in human urine (Axelson et al., 1982), studies of
isoflavones in humans began in the 1980s. Much of the early PE research focused on
the relative oestrogenicity of these compounds – using assays such as growth
promotion in oestrogen receptor-positive breast cancer cell lines or increases in
uterine weights of mice to assess their stimulatory potential in oestrogen-responsive
tissues.
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PE are capable of producing both oestrogenic and anti-oestrogenic effects depending
upon the tissue type, the proportion of α- to β-type oestrogen receptors and the
concentration of their endogenous ligands (Ososki & Kennelly, 2003). PE induce a
partial response upon binding to oestrogen receptors, so in an oestrogen-deprived state
(for example, in the ovariectomised rodent or in the relatively low-oestrogen
environment after menopause) PE increase the transcription of oestrogen-dependent
genes. In an oestrogen-rich environment, these weak partial agonists effectively act
as oestrogen antagonists by blocking endogenous oestrogens from receptors. For this
reason, PE are classed as selective oestrogen receptor modulators or SERMs.
Interest in the effects of PE on human health grew rapidly after the observation that
Asian populations with a high dietary intake of PE (and particularly of soya
isoflavones) have a lower incidence of hormone-dependent cancers relative to
Western populations whose habitual PE intake is low. The incidence of breast and
prostate cancers in Asians increases within one or two generations after migration to a
Western country, evidence that protection against these cancers is attributable to some
aspect of Asian diet or lifestyle (Griffiths et al. 1996). Further epidemiological
studies investigated Asian diets and the incidences of chronic diseases such as cancers
and cardiovascular disease in these populations. Many of these studies highlighted
soy as a potential protective factor (Adlercreutz, 2003; Dai et al., 2002; Fournier et
al., 1998; Greenstein et al., 1996; Hirayama, 1986; Hirose et al., 1985; Nagata, 2000;
Nomura et al., 1978; Yuan et al., 1995). Simultaneously, mechanistic studies were
undertaken to elucidate a mechanism by which the Asian diet could protect against
these Western diseases (Adlercreutz & Mazur, 1997; Anderson et al., 1999; Messina
et al., 1994). Isoflavones in soy were a candidate for mediating such a protective
effect.
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CHEMISTRY OF PHYTOESTROGENS
Phytochemicals with oestrogenic properties fall into a number of chemical classes.
The relationships between classes of PE commonly responsible for physiological
effects in humans are shown in Table 1 but this is by no means an exhaustive list of
phytochemicals with oestrogenic properties. Compounds shown in brackets are
metabolites of PE.
Table 1: Classes of PE
Flavonoids Non-Flavonoids
Isoflavones Prenyl flavonoids Coumestans Lignans
Genistein
4’,5,7-
trihydroxyisoflavone
8-prenylnaringenin Coumestrol Lariciresinol
Daidzein
4’,7-
dihydroxyisoflavone
6-prenylnaringenin Isolariciresinol
Glycitein
4’,7-dihydroxy-6-
methoxyisoflavone
Xanthohumol Matairesinol
Biochanin A
5,7-dihydroxy-4’-
methoxyisoflavone
Isoxanthohumol Secoisolariciresinol
Formononetin
7-hydroxy-4’-
methoxyisoflavone
[enterodiol
2,3-bis(3-
hydroxybenzyl-butane-
1,4-diol]
[equol
7-hydroxy-3-(4’-
hydroxyphenyl)-
chroman]
[enterolactone
trans-2,3-bis(3-
hydroxybenzyl)-
butane-1,4-diol]
Of these compounds, those found most often and in the greatest concentration in
human blood and urine are isoflavones and mammalian lignans. Enterodiol and
enterolactone are the mammalian lignans, so named because they are formed by the
action of microflora in the mammalian intestine upon the plant lignans (Adlercreutz &
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Mazur 1997). Isoflavonoids are thought to have evolved about 120 million years ago
via the flavone biosynthetic pathway (Adlercreutz, 1998).
Equol, an isoflavone derivative (or more correctly an isoflavan), is a product of
intestinal bacterial enzymatic action on daidzein (Setchell et al., 2002). In foods,
isoflavones are usually present as glycosides (Coward et al., 1993) or their methyl
derivatives which may be conjugated to acetyl or malonyl groups at the sugar moiety.
Genistein, daidzein and glycitein glucosides are named genistin, daidzin and glycytin.
Biochanin A and formononetin are the 4’-methyl derivatives of genistein and daidzein
and constitute the aglycone moieties of ononin and sissotrin (COT 2003b). Glycitein
is the 6-methoxy analogue of daidzein but is not converted to daidzein or equol to any
appreciable extent in vivo because of the proximity of the 6-methoxyl group to the 7-
hydroxyl group which hinders demethylation (Setchell et al. 2002). Structural
formulae of isoflavones and their glucosides are illustrated in Appendix 1.
Conjugation to glucose in the plant or to glucuronide and sulphate in mammals
increases the hydrophilicity of isoflavones. These glucuronide and sulphate
conjugates can be hydrolysed by acid and/or heat as well as by enzymatic
degradation. Fermentation of soy beans (as in the production of miso and tempeh)
hydrolyses the glycosides (COT 2003b). Isoflavone aglycones are heat stable
(Setchell, 1998), hydrophobic and acid stable (COT 2003b), the presence of phenolic
groups in both ends of the molecule rendering exceptional stability upon these
compounds (Adlercreutz & Mazur 1997).
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All PE are structurally similar to oestradiol (Mazur & Adlercreutz, 2000; Miksicek,
1995) as they bear phenolic rings in similar positions and are close in molecular
weight. In addition, the A ring of isoflavones can mimic the A ring of oestrogens and
there is an almost identical distance (11Ǻ) between the two aromatic hydroxyl groups
of the isoflavone nucleus and the C3 and C17 hydroxyl groups of oestradiol. The
pattern of hydroxylation of isoflavones also appears to be a determinant of
oestrogenicity, with hydroxyl groups in the 4’, 5 and 7 positions (as in genistein)
being optimal for oestrogen receptor binding (Miksicek 1995; Mazur and Adlercreutz
2000). The structural similarity of PE to oestradiol is illustrated in Appendix 2.
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ISOFLAVONES IN THE DIET
These small, stable and physiologically active compounds occur commonly in the
human diet. Dietary exposure to isoflavones comes principally from soy (raw soy
beans are estimated to contain 142mg total isoflavones per 100g (Ritchie, 2003a) –
and high isoflavone intakes in Asia are attributable mainly to soy foods (Arai et al.,
2000). In the West, the major source of isoflavones is ‘hidden soy’ in bakery products
and processed meats, although consumption of soy milks and ‘second generation’ soy
foods such as soy-based meat substitutes is becoming increasingly widespread
(Ritchie et al., 2005a). Most studies have found that the richest sources of isoflavones
in the Western diet are soy products, bakery products and dried fruits (Ritchie et al.
2005a)(Clarke & Lloyd, 2004; Horn-Ross et al., 2000). Isolated soya isoflavones as
supplements are also widely available over the counter, widely used and currently
being investigated for their clinical utility, safety and pharmacological properties.
Genistein and daidzein are the most prevalent dietary isoflavones, comprising 90% of
the total intake of oestrogenic isoflavonoids (Pillow et al., 1999). Although food
processing can alter the concentrations of genistein and daidzein in foods and may
influence the ratio of genistein to daidzein (Coward et al., 1998; Slavin et al., 1998),
the presence of genistein, daidzein and glycitein in the ratio 1 : 0.8 : 0.1 in soybeans
and their derivative foods is typical (Clarke & Lloyd, 2004). Biochanin A and
formononetin are found mainly in clover and alfalfa sprouts (Franke et al., 1998;
Mazur et al., 1996) and are therefore much less prevalent in the average diet than
genistein and daidzein.
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Estimates of the mean (and range of) total dietary intakes of isoflavones in various
populations are presented in Table 2. Where mean intakes were not reported, the
range alone is given in brackets.
Table 2: Isoflavone intakes in various populations
Authors Population Mean isoflavone
aglycone intake
(mg/d)
Methods used Sample
size
Clarke and
Lloyd 2004
UK 3 Direct food analysis
extrapolated to
average adult food
consumption
20 diet
samples
Verkasalo et
al. 2001
UK (0-34) 7-day food diaries 80
Clarke et al.
2002
UK
(vegetarians)
10.5 Duplicate diet
analysis
35
Guthrie et al.
2000
Australian (0-340) FFQ 354
Lampe et al.
1999
USA (0.5-2) 5-day food diaries 103
Horn-Ross et
al. 2000
USA 2.6 FFQ 447
De Kleijn et al.
2001
USA 0.2 FFQ 964
Nagata et al.
2000
Japanese 29 3-day food diaries 6000
families
Arai et al.
2000
Japanese
women
46.5 3-day food diaries 106
Yamamoto et
al. 2001
Japanese 50 FFQ 215
Yamamoto et
al. 2001
Japanese 38 4x 7-day food diaries 215
Ritchie et al.
2005
Scottish
omnivores
1.2 7-day weighed diaries 9
Ritchie et al.
2005
Scottish
vegetarians
7.4 7-day weighed diaries 10
Ritchie et al.
2004
Scottish
women
(0-53.1) 7-day food diaries 15
Ritchie et al.
2004
Scottish 3.7 (0.05-39) 24-hour food records 21
FFQ = food frequency questionnaire
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Of note is the particularly wide range of intakes observed by Guthrie and colleagues
in Australia (0-340mg/d), which might be due to the presence of a significant
Indonesian minority in this population. Some authors put much higher estimates on
Japanese isoflavone intake than are indicated above, for example, Cassidy et al.
(1994) base their estimate of 150-200mg/d on their own measured concentrations of
isoflavones in soy foods and on Japanese dietary patterns reported by other
researchers. The distribution of isoflavones in Western population is positively
skewed by high intakes in a small subset of the population who consume soy on a
regular basis (Keinan-Boker et al., 2004; Ritchie et al., 2004; Verkasalo et al., 2001).
With increasing availability and popularity of isoflavone supplements, usually self-
prescribed for menopausal and menstrual symptoms, very high intakes may be
observed in this subset of the population.
Phytoestrogens and Lifestyle
Because PE are present in appreciable concentrations only in certain foods, PE intake
varies greatly with dietary habit. Dietary habits are in turn associated with other
social variables and lifestyle choices which therefore correlate with PE intake.
Keinan-Boker et al. (2004) reported that in 15555 Dutch women aged between 49 and
70, those in the highest quartile of PE intake were significantly older at delivery of
their first child, smoked significantly less, were significantly taller, had significantly
lower BMI and significantly higher physical activity. They also had significantly
higher daily intakes of energy, fibre, fruit, vegetables and soy produce. This would
seem to point towards a “high-phytoestrogen lifestyle” in which many of the attributes
of affluence and health-consciousness are clustered. This study also reported no
significant relation between isoflavone or lignan intake and breast cancer incidence,
Introduction
10
despite the apparently ‘healthier’ lifestyle of the high PE consumers. However, some
lifestyle characteristics of affluent women, such as older age at delivery of their first
child, are positively associated with breast cancer risk. In China, where affluence is
associated with a more Westernised lifestyle, breast cancer is sometimes colloquially
referred to as “the rich woman’s disease” (Plant, 2000).
The traditional Asian diet which has been observed to protect against cancers and
other Western diseases is also low in dairy produce (Plant 2000), fat and red meat and
rich in vitamin D (Adlercreutz, 2003) and n-3 fatty acids.  Β-carotene has also been
observed to confound associations of PE with cancer in some studies (Murkies et al.,
2000).
Adlercreutz has suggested that lignans may serve as a “biomarker of a healthy diet”
(2003) due to their presence alongside high intakes of vegetables, fruits and fibre.
Fibre and urinary and serum lignan concentration correlate significantly but not
strongly (Grace et al., 2004).
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PHYSIOLOGICAL EFFECTS OF ISOFLAVONES
Isoflavones, being lipid soluble, stable in structure and of a low molecular weight, are
able to cross the cell membrane by passive diffusion and act upon nuclear oestrogen
receptors. Every organ system in the body expresses oestrogen receptors to a greater
or lesser extent in its various tissue types, hence the oestrogen receptor-mediated
activities of PE are extremely widespread.
Isoflavones may also interact with membrane receptors and exert effects that are
expressed through second messengers in the cytoplasm. Non-oestrogen receptor-
mediated actions include protein tyrosine kinase inhibition (Akiyama et al., 1987);
inhibition of cytochrome P450 enzymes (which are capable of metabolising pro-
carcinogens to active carcinogens) (Badger et al., 2002); inhibition of angiogenesis
(Fotsis et al., 1993); reduction in oxidative damage of both DNA (Djuric et al., 2001;
Mitchell & Collins, 1999) and lipoproteins (Vedavanam et al., 1999); altering the
expression or function of enzymes including topoisomerase (Bertrand et al., 1993;
McCabe & Orrenius, 1993; Yamashita et al., 1990), glutathione peroxidase, catalase,
superoxide dismutase, glutathione reductase and glutathione-S-transferase (Cai &
Wei, 1996); inhibition of the transcriptional regulator NFκB (Davis et al., 1999;
Dijsselbloem et al., 2004); modulation of cyclins and cyclin-dependent kinase
inhibitors (Choi et al., 2000; Sarkar & Li, 2002); modulating expression of pro-and
anti-apoptotic genes such as Bax and Bcl-2 (Sarkar & Li 2002); and regulation of
growth factors and growth factor receptors in both malignant and non-malignant cells
(Boersma et al., 2001). Thus, this group of molecules are considered to have
immense potential to modify physiological and pathophysiological processes.
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Among the most studied clinical effects of PE are in the prevention and management
of cancer, cardiovascular disease and other hormone-related diseases, such as
osteoporosis.
Phytoestrogens and Endocrine Physiology
Premenopausal women – sex hormone metabolism and the menstrual cycle
Increases in menstrual cycle length by three and a half days, accompanied by
decreases in serum oestradiol and progesterone, have been observed after one month
of soy supplementation (approximately 100mg/d genistein plus 100mg/d daidzein)
(Lu et al., 1996). A significant increase in the length of the follicular phase of the
cycle was observed in six women supplemented with only 45mg/d isoflavones for one
month (Cassidy et al. 1994). This increase correlated significantly with urinary equol
excretion, indicating that this isoflavone metabolite may be largely responsible for the
effects on the menstrual cycle. Increase in follicular phase length was accompanied
by statistically significant increase in the concentration of circulating oestradiol in the
follicular phase and suppression of the mid-cycle peaks of LH and FSH.
Circulating oestrogen concentrations are considerably lower in the follicular than in
the luteal phase of the cycle, so lengthening of the follicular phase is associated with a
reduced exposure to oestrogens over time. Reducing exposure to oestrogen may be
significant for breast cancer prevention as well as for conditions of oestrogen excess
such as menorrhagia, uterine fibroids and some forms of premenstrual syndrome.
However, lengthening of the menstrual cycle may be considered an adverse effect in
women with oligomenorrhoea or polycystic ovarian syndrome.
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One study has assessed the impact of soy protein containing 68mg/d isoflavones on
premenstrual symptoms after two months of supplementation. Significant
improvements compared to placebo were seen in breast tenderness, headaches,
cramps and swelling but differences in total symptoms were not significant (Bryant et
al., 2005).
Effects on sex hormone metabolism in postmenopausal women
In postmenopausal women, neither 56mg/d nor 90mg/d isoflavones administered as
part of a soy protein isolate for three- or six-month periods had any effect on serum
hormones (Persky et al., 2002). Similarly, Wu et al. (2005) showed no effect of
supplementing 50mg/d for 8 weeks and Foth & Nawroth (2003) reported no effect
upon any serum hormones after supplementing 20mg/d for 24 weeks. Isoflavones
extracted from red clover (26mg biochanin A, 16mg formononetin, 1mg genistein and
0.5mg daidzein) did not produce any alterations in circulating oestradiol, FSH (follicle
stimulating hormone) or LH (luteinising hormone) in postmenopausal women after
one year of supplementation (Atkinson et al., 2004). A study of 144 postmenopausal
women in Singapore found that soy intake (as assessed by food frequency
questionnaire) was significantly associated with serum oestrone independently of any
non-dietary factors, with those in the highest quartile of soy intake having 15% lower
circulating oestrone than those in the lowest quartile (Wu et al., 2002).
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Phytoestrogens, sex hormones and breast cancer risk
In postmenopausal women, circulating oestrogens are low and oestrone dominates in
the plasma. The ratio of breast tissue to plasma oestradiol concentration is 1:1
premenopausally but rises to 10:1 or 50:1 after menopause. Oestradiol concentrations
in the breast are primarily regulated by aromatase, oestrogen sulphatase and 17β-
hydroxysteroid dehydrogenase (17β-HSD). The entry of oestrone into breast cells is
controlled by the de-conjugating enzyme oestrone sulphatase (Dai et al., 2003). The
activity of these enzymes may therefore be much more important than circulating
oestrogen levels for determining the carcinogenic effects of oestrogens on the breast
in postmenopausal women. Genistein, biochanin A, enterolactone, enterodiol and, to
a lesser degree, equol, formononetin, daidzein and coumestrol inhibited 17β-HSD in
genital skin fibroblasts (Evans et al., 1995) . Genistein inhibits this enzyme in breast
cancer cells in culture (Wong & Keung, 1997). Daidzein inhibits oestrone sulphatase
in vitro (Adlercreutz et al., 1993).
In one study which reported an inverse relationship between urinary isoflavones and
breast cancer risk (Makela et al., 1994) the association was significant only in women
who had low levels of sulphated oestrone (indicating higher levels of oestrone
sulphatase activity), high levels of oestradiol and low levels of sex hormone binding
globulin (SHBG). These three factors would create a more oestrogenic environment
and consequently a higher risk of breast cancer. It could therefore be speculated that
PE might exert the observed anti-carcinogenic effect by competing with oestrogen at
the receptor level, upregulation of SHBG synthesis, inhibition of oestrone sulphatase
or all of these actions. Alternatively, it may be that there is no mechanistic relation
between this triad of high-oestrogen states and PE chemoprevention, but simply that
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the risk in this high-oestrogen group is sufficiently high for a protective effect of PE
to reach statistical significance.
Lower circulating concentrations of SHBG are associated with increased breast cancer
risk (Adlercreutz et al., 1989; Lipworth et al., 1996). SHBG binds oestradiol and has
been found to antagonise its growth-promoting on MCF-7 human breast cancer cells
in culture (Fortunati et al., 1996). SHBG synthesis may be stimulated by PE
including genistein, daidzein and equol (Adlercreutz et al., 1987; Loukovaara et al.,
1995; Mousavi & Adlercreutz, 1993). Adlercreutz and Mazur (1997) reported
significant increase in SHBG (from 55.7 to 71.2nmol/l; p<0.01) in postmenopausal
women after three months’ supplementation with soy and flaxseed but other dietary
intervention studies have reported no effect of PE on SHBG concentrations in plasma
(Cassidy et al., 1994; Cassidy et al., 1995; Nagata et al., 1997; Phipps et al., 1993).
Higher plasma concentrations of SHBG are observed in vegetarians and subjects with
high urinary PE excretion (Adlercreutz et al., 1987; Setchell, 1998) but at present it is
not possible to determine whether associations with SHBG are due to an effect of PE
or some other aspect of the plant-based diet. For example, vegetarians generally have
lower plasma insulin levels, which may increase plasma SHBG independently of
dietary phytochemicals (Loukovaara et al., 1995). Circulating concentrations of
SHBG show great variation both between and within individuals so detecting an
effect of small magnitude upon circulating SHBG is very difficult (Adlercreutz &
Mazur 1997). In the above studies, basal SHBG was already relatively high, reducing
the potential for increase by PE.
If observational but not intervention studies report demonstrable effects of PE on
SHBG concentrations, this may be because a high-PE diet must be consumed over a
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long time period or early in life in order to produce an effect. Alternatively, it may
indicate that co-existent lifestyle factors and not the PE concentration of the diet are
responsible for maintaining high SHBG concentrations.
SHBG is of relevance not only for breast cancer risk reduction, but also for other
conditions of oestrogen dominance such as polycystic ovarian syndrome, uterine
fibroids and endometriosis, in which an increase in circulating SHBG would
theoretically be beneficial.
The relative ratios of different oestrogen metabolites are of relevance for the risk of
female cancers because while 2α-hydroxyoestrone (2OHE) has relatively little
biological activity, 16α-hydroxyoestrone (16OHE) promotes hormone-dependent
cancer growth (Brooks et al., 2004). Xu and colleagues (2000) found that
supplementation with 65mg/d isoflavones increased the urinary ratio of 2OHE relative
to 16OHE in postmenopausal women. They also reported a decrease in urinary 4-
hydroxyoestrone with both 65mg/d and 123mg/d isoflavone supplementation and an
increase in the ratio of 2OHE : 4OHE at 7.1mg/d, 65mg/d and 123mg/d. Brooks et al.
(2004) supplemented soy flour providing 41.9mg/d isoflavones to 46 postmenopausal
women and found no significant relationship with the ratio of 2OHE to 16OHE.
However, these studies are not directly comparable because a lower isoflavone dose
was administered by Brooks et al.
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Menopausal symptoms
Soy isoflavone and other PE supplements are commonly self-prescribed by women
for the treatment of hot flushes and other menopausal symptoms (Quella et al., 2000),
although the findings of clinical trials assessing their efficacy have been, at best,
mixed (Albertazzi et al., 1998; Murkies et al., 2000). A systematic review by Krebs
et al. (2004) concluded that PE are ineffective for the treatment of hot flushes but
other authors consider that PE do have a beneficial effect, albeit one that is significant
only in women who have more than five flushes per day (Messina & Hughes, 2003).
PE, either as supplements or included in the diet, are also frequently used by women
for the treatment of menopausal symptoms after breast cancer or during anti-oestrogen
treatment for breast cancer, when conventional hormone replacement therapy is
contraindicated. Hot flushes in breast cancer survivors are a significant clinical
problem and are often more severe when medically induced than as a consequence of
natural menopause (Quella et al. 2000). During a double-blind crossover study of 149
breast cancer survivors suffering hot flushes severe enough to require intervention,
150mg of soy isoflavones in three divided doses for four weeks produced no effect
discernible from placebo in terms of patient preference, frequency or severity of hot
flushes (Quella et al. 2000).
There is some evidence of a beneficial impact of PE on cognition in postmenopausal
women (File et al., 2002), which will be discussed later.
Despite some negative findings, soy and PE supplements continue to be popular
among menopausal women and anecdotal evidence of efficacy is widespread. It is
conceivable that if introduction of PE into the diet brings about a general dietary
change, some other aspect of this dietary change is responsible for the alleviation of
symptoms and perceived efficacy of PE.
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Hormonal effects of PE in men
In fifteen 18-35 year old men, two-month administration of a soy extract containing
40mg/d isoflavones induced no changes in oestradiol, testosterone, FSH or LH,
testicular volume or sperm count, volume, motility or morphology (Mitchell et al.,
2001). An inverse correlation between soy product intake and oestrogen levels in
men was observed by Nagata et al. (2000) although the same group found that dietary
supplementation with 400ml soy milk daily for 8 weeks did not result in any alteration
of total oestrogen concentrations in men, despite a reduction in serum oestrone.
Fertility and development
Concerns over the safety of PE have centred around their potential impact on human
fertility and infant development. However, reliable clinical data in this area are
extremely difficult to obtain. A review in 2002 of the health consequences of early
soy consumption concluded that no long-term adverse effects of early exposure are
evident up to young adulthood but that little is known about any effects (adverse or
beneficial) on health in later life (Badger et al., 2002). The body of evidence
regarding PE effects on fertility and development is based almost entirely on rodent
(and, to a lesser extent, primate) studies. These suggest that genistein produces a
limited degree of oestrogenic effect such as advancement of puberty, mammary gland
differentiation, irregular cycling and abnormal histology of the reproductive tract.
Exposure in the perinatal, neonatal and prepubertal stages produce the most marked
effects in animals. However, extrapolation to humans is extremely difficult because
many of the animal studies have used subcutaneous administration of PE, bypassing
intestinal and hepatic metabolism, or have fed soy-based diets without recording their
PE content. Significant species differences also exist, both in the hormonal control of
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sexual development (COT, 2003c) and in the metabolism of PE, making the data
difficult to interpret.
Phytoestrogens and the thyroid
Isoflavones are structurally similar to the thyroid hormones, tri-iodothyronine (T3)
and thyroxine (T4) and have shown some goitrogenic effects (although without
producing hypothyroidism) in infants fed soy flour-based infant formula in the 1960s.
Subsequently, iodine was added to formulae and no such effects have been reported
since (COT, 2003d).
Isoflavones could theoretically increase concentrations of thyroid binding globulin
(TBG), thereby lowering free thyroxine and consequently increasing thyroid
stimulating hormone (TSH). In the healthy state, compensation would occur but if
thyroid function were compromised, increases in TBG might reduce free thyroxine
sufficiently to be clinically significant.
In postmenopausal women, no difference in TBG concentration was observed
between women supplementing with 118mg/d isoflavones in soy protein isolate and
those on placebo (Teede et al., 2004). Persky et al. (2002) saw increases in TSH in
postmenopausal women taking 90mg/d isoflavones compared to a placebo group.
However, these increases were small and unlikely to be clinically significant. A study
using the same dose of isoflavones did not find any differences in TSH, T4 or T3
between the isoflavone and placebo groups (Bruce et al., 2003). A Japanese study
(Ishizuki et al., 1991) reported hypothyroid symptoms and increases in TSH in
subjects eating 30g soybeans per day in addition to their usual diets. However,
isoflavone content of the soybean supplement and of the background diet was not
reported. Concentrations of inorganic iodide were lower during the soybean
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administration and the effect upon serum TSH was most pronounced in the older
group of subjects (mean age 61 years). Although TSH increased significantly, it
remained within normal parameters and serum T3 and T4 remained unchanged.
Overall, the data suggest that any effect of isoflavones on the thyroid is likely to be
clinically important only when thyroid function is compromised, for example by
iodine deficiency or advanced age.
Effects of Phytoestrogens in other physiological systems
Phytoestrogens and the cardiovascular system
Mortality due to cardiovascular disease (CVD) is lower in Eastern than in Western
populations and this is thought to be at least partly due to dietary differences. There
are a number of mechanisms by which soy foods might reduce CVD risk but no
strong evidence that any of these is due to its isoflavone content.
The hypocholesterolaemic effect of soy has been established in a meta-analysis of 38
controlled clinical trials (Anderson et al., 1995). Biomarkers of in vivo lipid
peroxidation are also reduced and the resistance of LDL to oxidation is increased after
soy consumption (Wiseman et al., 2000).
However, studies using purified isoflavones have produced inconsistent results (COT,
2003f). Similarly, soy diets have been shown to reduce blood pressure in human
studies (Teede et al., 2001; Vigna et al., 2000; Washburn et al., 1999) although two
studies have shown no effect of isolated isoflavones (Han et al., 2002; Simons et al.,
2000) and another demonstrated an improvement in systemic arterial compliance
without concomitant effect on arterial pressure (Nestel et al., 1997).
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Influences on vascular reactivity may be isoflavone-mediated, because both dietary
soy protein and intravenous genistein produce an oestrogen-like vasodilatory effect in
rhesus monkeys (Honore et al., 1997). In cultured human umbilical vein endothelial
cells the production of prostacyclin (a potent vasodilator) was significantly increased
in a dose- and time-dependent manner by genistein and daidzein (Hermenegildo et al.,
2005).
There is sufficient evidence to recommend inclusion of soy in the diet to reduce the
risk of CVD but as yet no basis for the recommendation of isoflavone supplements for
this purpose. If there is an effect of isoflavones in reducing CVD mortality or
biomarkers of CVD risk, then large, long-term intervention studies may be needed to
detect it. Such studies should assess plasma and urinary isoflavone concentrations in
relation to disease biomarkers and if isoflavone supplements are administered long-
term, markers of compliance will undoubtedly be required.
Phytoestrogens and bone
Studies in rodents have shown that PE consistently prevent bone loss after
ovariectomy (COT, 2003e). A major determinant of osteoporosis risk is the peak
bone mass attained in early adulthood, which may be affected by pre-pubertal
consumption of PE as occurs in countries where they form part of the traditional diet.
Rates of osteoporosis are lower in these countries (COT 2003e).
In the middle-aged, at-risk population, it seems that a relatively low threshold dose of
PE consumed over several years produces measurable effects on bone density
(Anderson et al., 1999). A two-year study by Lydeking-Olsen et al. (2004) reported
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that bone mineral content and bone mineral density in the lumbar spine were
maintained in a group taking two glasses of soy milk per day (containing 76mg/d
isoflavones) but decreased in the group on isoflavone-poor placebo.
The effects of isoflavones on bone are thought to be mediated through the oestrogen
receptors of osteoblasts (Anderson et al. 1999).
Phytoestrogens and the central nervous system
The biphenolic structure of isoflavones allows them to pass through the blood-brain
barrier and act on the CNS, where animal studies have revealed effects on various
brain structures such as the sexually dimorphic nucleus of the preoptic area and the
anteroventral periventricular nucleus (Lephart et al., 2005).
Isoflavones have demonstrable effects on cognition in humans and rodents, which
appear to show gender variations (Hill & Dye, 2003). File et al. (2001) randomised
15 male and 12 female students to soy supplements containing either 0.5 or 100mg/d
isoflavones for ten weeks before administering a battery of tests assessing four areas
of cognition. They observed significant enhancement of long-term episodic memory
(delayed verbal recall of pictures) and short-term non-verbal episodic memory in the
high isoflavone group. Mental flexibility as measured by rule shifting and reversal
improved slightly in the high isoflavone group while it deteriorated slightly in the low
isoflavone group. In terms of verbal fluency (word generation) and planning ability,
the women in the high isoflavone group showed improvements while the men showed
impaired performance. In a later study, the same group supplemented isolated
isoflavones (60mg/d) to 33 post-menopausal women (not taking HRT) for 12 weeks.
After this time they observed a greater improvement in episodic memory and frontal
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lobe functioning (sustained attention and speed of mental flexibility and planning
ability) in the supplemented group compared to the placebo group (File et al. 2002).
Whether these effects of isoflavones are oestrogen-receptor mediated is not known.
Phytoestrogens, immunity and inflammation
Oestrogens and xenoestrogens are well known to influence the immune system,
therefore PE were hypothesised to exert immunomodulatory influences. However,
experimental results to date have been contradictory.
Studies in rodents have produced reductions in thymus weight, lymphopenia and
compromised humoral immunity after injected (2-200mg/kg bw/d) or dietary (1000-
1500mg/kg diet) genistein (Yellayi et al., 2002). In a study by Zhang et al. (1997),
daidzein administered to mice by oral gavage produced increases in thymus weight,
phagocytic activity, circulating T-cell concentrations and splenocyte-mediated cell
lysis at 20 and 40mg/kg bw/d, although 10mg/kg bw/d showed no effect. The doses
administered in these rodent studies were extremely large and, neglecting species
differences in metabolism, would be equivalent to 140-14,000mg/d injected genistein;
dietary genistein equivalent to a diet consisting entirely of raw soy beans (which
contain approximately 142mg isoflavones per 100g); or 700, 1400 or 2800mg/d oral
daidzein for a 70kg adult.
Cordle et al. (2002) and Ostrom et al. (2002) compared soy formula-fed infants with
breast fed infants and showed no decrement in immune function based on antibody
responses to vaccines, immune cell sub-populations and morbidity.
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Anti-inflammatory effects have been observed in animal models of inflammatory
bowel disease (0.1mg/kg bw/d) and collagen-induced arthritis (Verdrengh et al.,
2003).
Richard et al. (2005) observed diminished secretion of the pro-inflammatory
cytokines tumour necrosis factor-α (TNF-α) and interleukin-8 in human peripheral
blood mononuclear and polymorphonuclear leukocytes in vitro, after stimulation with
lipopolysaccharide and interferon gamma. TNF is a key mediator of inflammatory
reponses and may play a pivotal role both in bone resorption and in the development
of cancer (Huang et al., 2005).
TNF inhibiting properties were confirmed in a human study by Huang et al. (2005),
who found 67% decreased serum TNF-α, 57% decreased serum interleukin-1α and
14% decreased blood monocytes after 10 weeks consuming 36 ounces soy milk per
day, compared with pre-supplementation levels. This equates to 1.02 litres soy milk,
likely to contain approximately 8320mg total isoflavones. Jenkins et al. (2002) found
no effect of 10mg/d or 73mg/d isoflavones in 50g soy protein upon C-reactive protein,
serum amyloid A or TNF-α in 41 hypercholesterolaemic men and postmenopausal
women, although there was a trend towards increase in interleukin-6 after the 73mg/d
phase. This negative finding may support the hypothesis that large doses of
isoflavones are required to produce a measurable impact on circulating TNF-α., but
further intervention studies would be required to verify it.
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Phytoestrogens and the digestive system
Some research suggests that a PE-rich diet may modulate the luminal environment of
the GIT. Wiseman et al. (2004) noted an increase in faecal bacterial β-glucosidase
activity after 10 weeks’ consumption of a high-soy diet, indicating a modulation of
the intestinal microfloral population which might have physiological effects for the
host. Isoflavones may also have a role in chemoprevention of cancers of the colon
and rectum (Lechner et al., 2005).
Phytoestrogens and renal function
In animal models and in human subjects with chronic kidney disease, soy protein has
been shown to limit or reduce proteinuria and preserve renal function (Velasquez &
Bhathena, 2001). It is not clear whether these effects can be attributed to the
isoflavone content, although their effects on cell proliferation, the extracellular matrix,
inflammation and oxidative stress may be highly relevant to renal disease.
Summary
With so many diverse pharmacological properties in all physiological systems, the
impact of PE - and especially of isoflavones such as genistein and daidzein – on
human health has been the topic of considerable debate and research. However, some
data lack generalisability from experimental model to humans or are weakened by
methodological shortcomings (Yang et al. (1996) give examples of common
methodological pitfalls). There is a need for rigorous investigation of the biological
and dietary correlates of isoflavone exposure in humans, in relation to physiologically
and clinically relevant outcome measures.
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ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION
These highly biologically active molecules are ordinarily present in human diets and
human bodies. Isoflavones and lignans have been found in human fluids including
urine, plasma (Franke et al., 2002), prostatic fluid (Finlay et al., 1991; Morton et al.,
1997), saliva (Finlay et al. 1991), semen (Dehennin et al., 1982), amniotic fluid
(Foster et al., 2002) and breast milk (Franke et al., 1998). High concentrations of
isoflavones and lignans are found in the blood and urine of vegetarians (Adlercreutz et
al., 1986; Adlercreutz et al., 1982) and Asian populations (Adlercreutz et al., 1991;
Adlercreutz et al., 1993; Morton et al., 2002).
Transformation and uptake of phytoestrogens
Isoflavones exist primarily as glycosides in plants and are hydrolysed in the jejunum
by the action of bacterial β-glucosidases (Setchell, 2000). The total absorption of
isoflavones appears to be similar regardless of whether glycosides or aglycones are
ingested, though aglycones are absorbed faster (discussed later).
Absorption of intact glycosides has not been observed (Hendrich, 2002; Setchell,
2000), hence the bioavailability of isoflavones is dependent on the ability of the gut
microflora to hydrolyse their glycosides. Intestinal microflora also largely determine
the metabolic fate of isoflavones. In a simulator of the human intestinal microbial
ecosystem, inoculation with a faecal sample from an equol-producing individual was
followed by equol production in the simulator (Decroos et al., 2005). Inter-individual
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variation in metabolic pathways may also be due to differences in gut transit time
(Hendrich 2002) or polymorphisms in liver enzymes (Kulling et al., 2000).
Individuals may be categorised as ‘equol producers’ (plasma equol > 83nmol/L or
20μg/L; urinary equol > 1000nmol/L or 242μg/L) or ‘non-equol producers’ (plasma
equol < 40nmol/L or 10μg/L; urinary equol < 1000nmol/L or 242μg/L) (Setchell et
al., 2002). These cut-off values have been derived empirically because there is a large
demarcation between individuals who produce equol and those who do not.
Rats, due to their large caecum and abundant microflora, produce very large quantities
of equol which is therefore the predominant isoflavone derivative in rat plasma
(Brown & Setchell, 2001). Germ-free animals do not excrete equol (Axelson &
Setchell, 1981) and equol is not present in the urine of infants whose microflora have
not yet developed (Setchell et al., 1998), illustrating the importance of intestinal
bacteria in the production of this metabolite.
Most studies show that only about a third of Caucasians produce equol in response to
ingestion of daidzein (Setchell et al. 1998). However, studies in Japanese women
have observed 50-54% prevalence of equol production (Arai et al., 2000; Uchiyama et
al., 2001). Equol is excreted in urine predominantly on days 2 and 3 after ingestion,
with only traces of equol excreted during the first 24 hours. Serum concentrations of
13C equol peak 24h after administration of 13C daidzein (Setchell et al., 2003a).
Isoflavone aglycones are rapidly conjugated at the hydroxyl groups by UDP-
glucuronyl transferases and sulphotransferases (Hendrich 2002) before undergoing
enterohepatic cycling (Setchell, 2000). It is generally assumed that glucuronide and
sulphate conjugates are biologically inactive (Hendrich 2002) but displacement of
oestradiol from receptors in murine uterine cytosol and enhancement of natural killer
Introduction
28
cell-mediated cytotoxicity have been demonstrated by daidzein and genistein
glucuronides (Zhang et al., 1999).
Glucoronide conjugates predominate over sulphates; the proportions of free aglycones
in plasma are small and the proportion of free aglycone in urine is smaller still
(Hendrich 2002).
PE may interact with oxidants such as HOCl, HOBr and ONOO- produced by
inflammatory cells to form brominated, chlorinated or nitrated derivatives. Boersma
et al. (2001) discovered a novel chlorinated metabolite of biochanin A formed by
human polymorphonuclear cells (PMN) upon stimulation of a respiratory burst. The
biochemical properties of such compounds are completely unknown but the presence
of a chlorine group, particularly in the 3’-position on the B-ring, may augment the
antioxidant properties of isoflavones. The capacity of human neutrophils to chlorinate
and nitrate genistein was later confirmed by D’Alessandro et al. (2003). Reactions
occurring in PMN are relevant to atherosclerotic plaques and tumours because PMN
aggregate in these lesions (Boersma et al. 2001). A low level of nitration of the
compound was constitutive while the extent of chlorination was markedly increased
by stimulation of the neutrophils.
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Phytoestrogens in the blood
Watanabe and colleagues (1998) reported that plasma concentrations of genistein and
daidzein increased within two hours after ingestion of baked soybean powder and
peaked after 6 hours. Other studies have reported peak plasma isoflavone
concentrations at 5.6 hours (Bloedon et al., 2002) genistein peaks at 5.5 hours and
daidzein peaks at 7.4 hours (Setchell 2003). These data are not contradictory - since
genistein is the dominant isoflavone in plasma, peak genistein concentrations rather
than daidzein concentrations, will determine the tmax of total isoflavones.
Studies using isolated isoflavones have reported shorter times to reach peak plasma
concentration, for example, 4 hours (Izumi et al., 2000) and 3-5 hours (Busby et al.,
2002).
In a recent study (Kano et al., 2006) orally administered isoflavone aglycones in soy
milk produced peak concentrations in plasma after only one hour, compared with 6
hours for isoflavone glucosides. However, in one study of 16 female subjects in
which 13C-labelled genistein and daidzein were administered orally, peak plasma
genistein concentrations were observed at 5.5 hours and peak plasma daidzein
concentrations at 7.4 hours, resembling more the pattern of conjugated or food-state
isoflavones. The serum half-lives of genistein and daidzein in this study were 7.77
hours and 7.75 hours, respectively. It is clear that the absorption kinetics of
isoflavones vary according to the formulation used but for isoflavone glycosides peak
plasma concentrations between 5 and 7 hours after ingestion appear reproducible.
Setchell et al. (2003a; 2003b) have reported evidence suggesting that isoflavone
bioavailability may not increase linearly with increasing dose. Specifically, they
report that percentage urinary recovery of daidzein at 0.4mg/kg was 34.5% and at
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0.8mg/kg was 25.6% (Setchell et al., 2003a). It must be stated that no conclusions
regarding the non-linearity of relationship between dose and percentage recovery can
be reached from only two dose groups, but the same authors also reported a non-linear
relationship when plasma isoflavone bioavailability (as measured by AUCinf) was
plotted against three different doses of isoflavones from soy nuts (Setchell et al.,
2003b). Again, three points cannot prove a relationship but the data certainly warrant
further investigation.
Genistein concentrations in plasma are consistently higher than daidzein
concentrations (Adlercreutz et al., 1993; Arai et al., 2000; Djuric et al., 2001; Franke
et al., 2002; Izumi et al., 2000; Morton et al., 2002; Morton et al., 1994; Sanders,
2002). In urine, concentrations of daidzein are higher than those of genistein. Higher
daidzein than genistein concentrations in urine correspond to more rapid clearance by
the kidney and a larger volume of distribution for daidzein (Setchell et al. 2003a).
Isoflavones bind to plasma proteins with a lower affinity than do endogenous
oestrogens, so they are more able to enter the cells. Nagel et al. (1998) demonstrated
that isoflavones have a greater binding affinity to oestrogen receptors (relative to
oestradiol) when applied to cell cultures in 100% serum compared to their application
in a serum-free medium. This has profound implications for the interpretation of
many in vitro studies, most of which use serum-free or 10% serum media for
carcinogenetic studies in breast and prostate. In these media, the effective free
fraction of isoflavones is reduced so their biological activity may be underestimated.
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The half-life of plasma disappearance of isolated isoflavones is 7.9 hours after a
single 50mg oral dose (Setchell, 1998). For isoflavones from baked soybean powder,
the plasma half life was 5.79h for daidzein and 8.36h for genistein (Watanabe et al.
1998). Plasma appearance and disappearance is similar in pre- and post-menopausal
women (Setchell 2000) and no clear age-related differences are reported (Setchell
1998).
Progressive accumulation of isoflavones in plasma during a four-week period of
supplementation was reported by Izumi et al. (2000) but could not be supported by
subsequent investigations (Ritchie et al., 2004a; Ritchie et al., 2004b; Setchell et al.,
2003a) so may have been an artefact of one study.
Plasma concentrations of isoflavones from populations consuming different habitual
diets are presented in Table 3.
Plasma isoflavone concentrations are markedly higher in Japanese people than in
Europeans and higher in vegetarians than in omnivores.
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Table 3: Plasma concentrations of isoflavones from populations consuming
different habitual diets
Authors Subjects Analytical
Method
Genistein
nmol/L
Daidzein
nmol/L
Equol
nmol/L
Enterolactone
nmol/L
Morton et
al. 2002
Japanese
men
GC-MS 492* 282* 99.1* 32.6*
Morton et
al. 2002
British men GC-MS 33.2* 17.9* 0.57* 24.4*
Morton et
al. 2002
Japanese
women
GC-MS 501.9* 246.8* 57.6* 22.7*
Morton et
al. 2002
British
women
GC-MS 27.7 12.5 2.2 18.7
Adlercreutz
et al. 1993
Japanese
men
GC-MS 276 107 ND ND
Arai et al.
2000
Japanese
women
TR-FIA 206.1** 72.5** ND ND
Adlercreutz
et al. 1993
Finnish
women
(omnivore)
GC-MS 9.25 6.3 ND ND
Adlercreutz
et al. 1993
Finnish
women
(vegetarian)
GC-MS 50 59.2 ND ND
Heald et al.
2006
Scottish
men
GC-MS 33.79** 18.00** 0.67$** ND
ND = no data presented; * serum concentrations; ** median plasma concentrations;
$ median of equol producers only
By comparison with circulating concentrations of oestradiol, serum concentrations of
isoflavones are very high. Thus, although PE have 100 or 1000 times lesser binding
affinity for oestrogen receptors, their presence in 10-10,000 times the concentration of
oestradiol means that they are capable of exerting physiological influence via
oestrogen receptor action. Appendix 3 illustrates this disparity between serum
concentrations of PE and oestradiol.
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Isoflavone excretion
Isoflavones are excreted in urine and minimally in faeces (Setchell et al. 2003a).
Isoflavone metabolites identified in human urine include methylequol, daidzein,
dihydrodaidzein, O-desmetholangolensin (O-DMA), genistein, 3’7-
dihydroxyisoflavan and formononetin. In faeces, daidzein, genistein, equol and O-
DMA have been measured (Adlercreutz & Mazur 1997). Other metabolites of
genistein and daidzein remain to be identified, as evidenced by stable isotope-labelled
studies (Setchell et al. 2003a). The percentage of the ingested dose excreted in urine
varies between 9-13% of genistein and 30-38% of daidzein (Setchell et al. 2003a;
Arai et al. 2000; Ritchie et al. 2004) and may decrease with increasing dose (Setchell
et al. 2003b). The elimination half-life may be influenced by the food matrix, with
isoflavones being more rapidly excreted when ingested in a liquid matrix than a solid
matrix (Setchell 2000). Studies report elimination half-lives for genistein and
daidzein (respectively) of 10.1 and 8.0 hours (Setchell et al. 2003b), 5.7 and 4.7 hours
(King & Bursill, 1998) and 6.0 and 3.8 hours (Shelnutt et al., 2000)
Table 4 shows 24-hour urinary excretion of PE in different populations. Urinary
isoflavone excretion is highest in the Japanese and higher in vegetarians than in
omnivores.
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Table 4: Urinary phytoestrogen concentrations in different populations
Author Subjects Analytical
Method
Descriptor Genistein
μmol/day
Daidzein
μmol/day
Equol
μmol/day
O-DMA
μmol/day
Enterolactone
μmol/day
Enterodiol
μmol/day
Arai et al.
2000
106 Japanese
women
HPLC-UV Median 10.79 20.54 15.74 1.64 ND ND
Adlercreutz
et al. 1995
10 Japanese
women
GC-MS Mean ND 2.5 0.5 ND ND ND
Adlercreutz
et al. 1995
10 recent Oriental
immigrants to
Hawaii
GC-MS Mean ND 0.2 0.08 ND ND ND
Adlercreutz
et al. 1982
10 omnivorous
American women
GC-MS Mean ND ND 0.14 ND 2.3 0.32
Adlercreutz
et al. 1982
10 vegetarian
American women
GC-MS Mean ND ND 0.14 ND 3.18 0.21
Ingram et
al. 1997
144 Australian
women
GC-MS Median ND 0.91 0.11 ND 3.1 0.32
Adlercreutz
et al. 1995
10 Finnish
omnivores
GC-MS Mean ND 0.2 0.1 ND ND ND
Adlercreutz
et al. 1995
10 Finnish
vegetarians
GC-MS Mean ND 0.41 0.09 ND ND ND
Wiseman et
al. 2004
76 British adults LC-MS Mean 1.0 2.5 0.5 0.4 ND ND
Ritchie et
al. 2004
14 Scottish adults LC-MS Mean 2.7 6.9 ND ND ND ND
ND = no data presented
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Isoflavones in tissues
The concentrations of isoflavones in tissues have yet to be adequately studied but the
large volume of distribution identified in pharmacokinetic studies (Setchell et al.
2003a; Setchell 2000) indicates a wide tissue distribution. Tissue concentrations of
PE will be a key area for future research because activities seen in vitro are
concentration dependent and have, at best, been compared with the concentrations
achievable in plasma rather than tissues.
Unpublished observations by Petrakis, Coward, Kirk and Barnes (1996) cited in
Peterson et al. (1998) suggest that free genistein is either readily and selectively
absorbed by breast tissues or deconjugated in the breast, because nipple aspirate fluid
from women consuming soy contained large quantities of unconjugated genistein,
moderate amounts of genistein-7-sulphate and little genistein β-glucuronide while
their blood contained mostly genistein β-glucuronide.
Preliminary work by Maubach et al. (2003) showed a 10-fold predominance of equol
in the breast tissue of one human subject relative to the concentrations of this
metabolite in serum and urine after isoflavone ingestion.
In rats, the ratios of free to conjugated genistein vary from 1:9 in the testis and 1:4 in
the female thyroid to 100% free genistein in the uterus and the male brain (Chang &
Doerge, 2000). In rats with implanted accessory sex gland tumours, very high doses
of genistein (50mg/kg bw administered subcutaneously) concentrated threefold less in
the tumours than in the blood (Schleicher et al., 1999).
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Given that isoflavone aglycones are lipophilic, it is reasonable to question whether
they may enter and accumulate in adipose cells. This has never been examined in
humans but might have implications for the effects of isoflavones on organs such as
the breast which have a large fat component and may act as a ‘sump’ for a variety of
lipophilic chemicals which may then be locally available to exert effects on the breast
epithelial cells. It is also unknown whether expression of intracellular oestrogen
receptors concentrates PE intracellularly. Expression of oestrogen receptor β might
be particularly important, given its higher affinity for PE.
Genistein and biochanin A have shown significantly different degrees of metabolic
transformation between normal and malignant breast cells in culture which may
explain the differential growth inhibition seen in these cells in response to these
compounds. MCF-7 malignant breast cells form the 7-O-sulphate ester of genistein
which is rapidly excreted from the cells. Normal breast epithelial cells in culture
appear to maintain higher intracellular concentrations than malignant MCF-7 cells
after application of the same initial isoflavone dose (Peterson et al., 1996), which
seems to support the findings of Schleicher et al. (1999).
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STUDYING PHYTOESTROGENS IN HUMANS
Epidemiological studies have been limited by difficulties in quantifying PE intake.
The use of dietary records to assess PE intake is always an approximation since the
concentration of PE in plants varies according to the season, variety and presence or
absence of plant pathogens. It is also difficult to estimate the percentage of soy in
processed foods which have not previously been analysed for PE. Development and
validation of databases of the PE content of foods is time-consuming and expensive.
Biomarkers are therefore an attractive alternative to quantify the PE intake of
individuals.
Some intervention studies (Maskarinec et al., 2002; Maskarinec et al., 2003) have
measured urinary PE as a marker of compliance but have simply demonstrated a
significant difference in mean urinary PE between the intervention and placebo
phases. These two studies used a soy food intervention (average 12 servings of soy
foods per week) and a supplement of 100mg/d isolated isoflavones, respectively.
Without a means of translating this level of prescribed intake to expected excretion,
individual compliance and the relationship between compliance and outcome (which
is especially important in long-term studies and those which require a major dietary
change) cannot be assessed.
The validity of 24-hour urine samples as biomarkers of isoflavone intake has been
assessed for intakes up to 53mg/d total isoflavones while the validity of spot urine and
plasma samples has been assessed for intakes up to 77mg/d.
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Plasma and 24-hour urine samples have been validated as biomarkers against
duplicate diet analysis (r = 0.92 and r = 0.97 respectively, p<0.001) (Ritchie et al.
2004). The mean total isoflavone intake in this study was 11mg/d.
Ritchie et al. (2004b) validated 24hour urine collections as a biomarker of intake in
supplemented and unsupplemented diets ranging from 0-53mg/d. Significant
correlation was found between total isoflavone intake and 24-hour urinary isoflavone
excretion (r = 0.89; p<0.001).
The same group validated timed spot urine and plasma samples as biomarkers of
intake using cereal bar supplements providing 28mg/d total isoflavones. Subjects
consumed their usual diets and dietary isoflavone intake which was estimated from
food diaries brought the range of intake to 0.05-77.3mg/d. The correlation of intake
with timed spot urine sample isoflavone concentration was r = 0.86, and of intake
with timed plasma sample concentrations was r = 0.88 (p<0.001 in both cases)
(Ritchie et al. 2004a).
Huang et al. (2000) found no correlation (r2 = -0.05, p = 0.85) between dietary and
urinary daidzein in 18 Caucasian women with a mean isoflavone intake of 2.2mg/d.
Mascarinec et al. (1998) found a significant correlation (r2 = 0.62, p = 0.0001)
between dietary and urinary isoflavones in a multi-ethnic sample of Hawaiian women
with isoflavone intakes between 5mg/d and 38mg/d.
Grace et al. (2004) investigated the relationships between dietary, urinary and serum
PE including isoflavones. This study involved large numbers of women, used
sensitive analytical methodology and assessed the relationship between biomarkers
and the range of intakes commonly observed in the UK. However, dietary isoflavones
were assessed using dietary records and a database of published values of the
isoflavone concentration of foods. This is significantly less accurate than duplicate
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diet analysis or the use of a food composition database validated for the purpose by
duplicate diet analysis. This study did find significant, though weak, correlations
between creatinine-adjusted spot urinary isoflavones and isoflavone intake (r2 = 0.27;
p<0.001) and between serum isoflavones and isoflavone intake (r2 = 0.31; p< 0.001)
for intakes up to 1.2mg/d.
Verkasalo et al. (2001) selected 80 participants on the basis of FFQ-assessed soy
intake to obtain a range of intakes before comparing isoflavone intake from 7-day
food diaries with plasma genistein and daidzein. Spearman correlation coefficients
for diary-based estimates of intake were between 0.66 and 0.8, while for the FFQ-
based estimates they were between 0.24 and 0.74. Isoflavone intakes in this study
ranged from almost zero in the lowest soy intake group to 49mg/d (assessed by FFQ)
or 33.7mg/d (assessed by 7d diary) in the highest soy group.
Takashima et al. (2004) compared genistein and daidzein content of hospital diets
with serum isoflavones in 22 prostate cancer patients and 66 controls. Overall, dietary
genistein correlated with serum genistein (r = 0.27) and dietary daidzein correlated
with serum daidzein (r = 0.33) but correlations were stronger in non-equol producers
(r = 0.52 for genistein; r = 0.67 for daidzein).
Using supplements of soy protein providing up to 36mg/d total isoflavones, Karr et al.
(1997) found a highly linear relationship between soy intake and isoflavone
concentration in 3 successive 24-hour urine collections but did not report correlation
coefficients. After adjustment for individual subject effect, they found that soy dose
accounted for 85% of the variability in daidzein excretion and 84% of the variability
in genistein excretion.
A study published by Arai et al. (2000) reported correlations (r2) between log plasma
genistein and log urinary genistein of 0.499; between log plasma daidzein and log
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urinary daidzein of 0.499; between log genistein intake and log urinary genistein of
0.346; between log daidzein intake and log urinary daidzein of 0.365; between log
genistein intake and log plasma genistein of 0.429; and between log daidzein intake
and log plasma daidzein of 0.335. This study used the authors’ previously published
tables of the isoflavone content of Japanese foods and dietary records to estimate
isoflavone intake, which may explain why correlations with biomarkers were not
strong. Plasma samples were also taken after an overnight fast, further weakening the
association with isoflavone intake since the half-life of plasma disappearance of
isoflavones is between 6 and 8 hours (Watanabe et al. 1998; Setchell 1998) and the
last consumption of isoflavone-containing foods would most likely have been at the
evening meal, perhaps 12 hours before blood sampling.
Atkinson et al. (2002) assessed the correlation between 24hour urine collections and
intake of soy foods assessed by food frequency questionnaire (FFQ) and dietary
records. However, as this study was carried out in an American population and other
authors have found the greatest contribution to isoflavone intake in Western
populations comes not from soy foods but from soy additives in other foods such as
bread and processed meats (Ritchie et al. 2005a; Clarke & Lloyd 2004; Horn-Ross et
al. 2000), it is likely that their estimates of intake were insufficiently accurate to
validate a biomarker. A similar study conducted in a Singapore Chinese population
(Seow et al., 1998) found no significant correlation between the frequency of soy food
consumption and isoflavone concentration in spot urine samples.
Other studies (Bhakta et al., 2005; Frankenfeld et al., 2003; Frankenfeld et al., 2002;
Heald et al., 2006; Yamamoto et al., 2001) have assessed the correlation between
biomarkers and soy or isoflavone intake as assessed by FFQ but this is generally to
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validate the FFQ rather than the biomarker. FFQ is an insufficiently accurate means
of assessing dietary intake to be employed in validating biomarkers. Duplicate diet
analysis or supplementation that is simple for participants to comply with are more
appropriate methods to measure this variable.
In general, a stronger correlation between intake and biomarkers has been observed
when the range of isoflavone intakes is greater. This is to be expected, and indicates
that a study aiming to validate a biomarker should assess the relationship between
intake and excretion over a wide range of intakes to ensure the best-fitting model for
relating the two variables.
Many studies have examined the effect of supplementary intakes far in excess of those
for which biomarkers have been validated (for example, 90mg/d (Bruce et al., 2003);
114mg/d (Teede et al., 2004); 132mg/d (Xu et al., 2000); 83mg/d (Adams et al.,
2004); 90mg/d (Anderson et al., 2002); 96mg/d (Gallagher et al., 2004); 5mg/kg bw
(Hutchins et al., 2005); 100mg/d (Maskarinec et al., 2002); 100mg/d (Mori et al.,
2004)). It is not yet known whether or not these higher intakes result in
proportionally greater availability of isoflavones to the target tissues.
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Summary
Isoflavones are ordinarily present in human biological fluids - their concentration
dependent on dietary intake - and exhibit a wide range of biological activity. The
pharmacological properties of these compounds, investigated in in vitro and animal
studies, coupled with the associations between isoflavone intake and health variables
in human populations, warrants further exploration into clinical and dietetic
applications. From the presently available data it is not possible to conclude whether
a) a diet high in isoflavones, or b) supplements of isoflavones can be recommended
for the treatment or prevention of disease. In order to draw such conclusions, research
in humans is required.
Such research must include biological measures of isoflavone exposure because
estimation of dietary isoflavones in free-living studies is extremely difficult.
Intervention studies should include biological markers of compliance, particularly if
the intervention requires a major dietary change or adherence to the protocol for a
prolonged period of time.
Before conclusions can be drawn regarding the efficacy or safety of large doses of
isoflavones and before the results of in vitro studies using high concentrations of
isoflavones can be extrapolated to humans, it is important to determine the oral
bioavailability of these compounds at higher doses.
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Aims
The primary aim of this study was to validate a biomarker suitable for application in
observational studies and intervention studies as a reliable measure of exposure to
dietary isoflavones.
A secondary aim was to determine whether plasma isoflavone concentrations or
urinary isoflavone concentrations during isoflavone supplementation up to 165mg/d
will reach a maximum beyond which they will not increase with increasing
supplement dose. This will be referred to as a plasma concentration plateau or a
urinary concentration plateau.
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METHODS
In order to investigate the relationship between isoflavone intake and isoflavone
concentration in 24-hour urine collections, timed plasma samples and timed spot urine
samples, a cross-over study was carried out in which each participant received three
different doses of isoflavones between 55 and 165mg total isoflavones per day. 24-
hour urine collections, timed plasma samples and timed spot urine samples were taken
at baseline and during each supplement phase for isoflavone analysis by liquid
chromatography and mass spectrometry (LC-MS). Correlations between the
biomarkers and between each biomarker and intake were assessed.
Study Design
Healthy volunteers were recruited by poster advertisement to a randomised, double-
blind, placebo-controlled, cross-over study. Each participant took oral supplements of
soy-derived isoflavones providing 48mg genistin, 5mg glycitein and 41mg daidzin.
48mg genistin is equivalent to 29.996mg genistein and 41mg daidzin is equivalent to
25.017mg daidzein. Thus the total genistein plus daidzein content of one tablet was
55mg. Full details of the isoflavone tablets and placebo tablet used are given in
Appendix 4.
A diagram of the study protocol is shown in Figure 1.
Ethical approval was granted by Fife NHS Research Ethics Committee and by the
Bute Medical School Ethics Committee.
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Figure 1: Study Protocol
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Figure 1 continued:
Optional Open Phase:
B = timed blood sample R = 24-hour dietary recall
U = timed urine sample 7D = 7-day food diary
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Each volunteer was screened prior to recruitment to ensure that they met the inclusion
and exclusion criteria, which were as follows:
Inclusion Criteria Exclusion Criteria
In good general health Antibiotic use within 6 weeks prior to
study commencement
Aged between 18 and 65 years Concurrent pregnancy
Concurrent participation in another
research trial
Any systemic illness affecting nutritional
status
Suitable volunteers were provided with an information sheet and invited to attend an
initial visit before giving written consent to participate. All volunteers were weighed
at the beginning and end of the study and their height measured. This was to ensure
that normal dietary intake was maintained during the study and for the purposes of
calculating basal metabolic rate (BMR) and body mass index (BMI).
Each volunteer completed three intervention phases, each one week long, in which
they received either 55mg isoflavones, 110mg isoflavones or placebo. The order of
the intervention phases was randomised and the phases were separated by wash-out
phases of one week duration. Participants who wished to continue with the study
entered an optional open phase after a further week of wash-out at the end of the
double blind phase. In this phase participants received 165mg of isoflavones per day
and attended study visits as before. Dietary intake of isoflavones was assessed for the
24-hours preceding each sample and estimated dietary intake added to supplementary
intake for each participant.
Timed blood samples, timed spot urine samples, 24-hour urine samples and 7-day
dietary records were obtained prior to supplementation to establish background
dietary intake and baseline levels of PE in blood and urine.
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Timed blood samples and timed spot urine samples were obtained at two study visits
during each intervention phase. A 24-hour dietary recall was obtained for the period
up to the first timed samples. Participants provided a 24-hour urine collection
between the two timed samples and a two-day dietary record over the period in which
they were collecting urine and providing the second timed blood and urine samples of
each phase. Spot urine samples were taken within half an hour of blood sampling.
Blood samples were drawn into heparinised vacutainers and kept upright at 4oC
overnight to settle before separation of plasma by aspiration using a disposable
pipette. Blood and urine samples were stored at -20oC until they were required for
analysis. Holder et al. (1999) have analysed isoflavone the content of plasma by LC-
MS before and after two freeze-thaw cycles and demonstrated a lack of effect on
plasma isoflavone concentrations of freezing and thawing.
The recruitment poster; pre-enrolment telephone interview schedule; participant
information sheet; consent form; letter to general practitioners; dietary recording
instructions and 24-hour urine collection instructions are given in Appendices 5 to 11.
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Dietary analysis
Dietary records were analysed using the software program Microdiet®, into which
were imported values for the PE content of foods from the database validated and
published by Ritchie (2003a). Portion sizes were converted to average weights using
a Ministry of Agriculture, Fisheries and Food (MAFF) booklet (Nelson et al., 1997).
Microdiet provided a measure of estimated PE intake and energy intake (kcal).
Accuracy of food recording was checked by comparing EI (energy intake) and BMR
(basal metabolic rate). Accuracy was assumed if the EI: BMR was greater than 1.2,
indicating that reported energy intake was sufficient to maintain health. BMR was
calculated using the Schofield equations published by the Department of Health
(1991).
24-hour urine collections
Participants were provided with two 2 litre containers containing 1g/l boric acid (as a
preservative), a plastic measuring jug, three 80mg PABA tablets, and a urine
collection record sheet. PABA recovery was used to measure completeness of
collections. Participants were instructed to discard the first urine that they passed on
the day of the collection but to record the time at which they did this. They were
instructed to collect every drop of urine passed until the same time the next morning.
PABA tablets were to be taken at approximately breakfast, lunch and dinner times,
although the last tablet had to be taken by 8pm. (Bingham & Cummings, 1982).
The total volume of urine passed was recorded. The entire collection was then
thoroughly shaken to ensure complete mixing and aliquoted into three labelled
universal containers and stored at -20oC. The remaining urine was discarded.
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Validation of urine collections using para-aminobenzoic acid
240mg/day para-aminobenzoic acid (PABA) was administered orally to subjects
while they were collecting 24-hour urine samples and its recovery in urine was
measured by spectrophotometry using the method of Bingham and Cummings (1982)
to assess the completeness of urine collections.
Sample preparation and methods
Standard solutions of PABA (Fluka) were prepared by dissolving 240mg PABA in
one litre of double-distilled water in a volumetric flask with the addition of six sodium
hydroxide pellets. Standard solutions of 180mg/l, 120mg/l and 60mg/l PABA were
prepared by dilution from the original stock solution and subsequently stored in glass
Duran bottles at 4oC.
All urine samples were prepared in triplicate. 100μl aliquots were pipetted into glass
stoppered boiling tubes and 5ml 2M NaOH added to each tube. 100μl aliquots of
each standard solution were also prepared in triplicate with the addition of 5ml NaOH
and were kept at room temperature for two hours while the urine samples were heated
in a water bath at 100oC. Heatproof silicone grease was used to lubricate the ground-
glass stoppers of the sample tubes to prevent sticking after heating, and stoppers were
removed while tubes were warm. After cooling, the following reagents were added to
each tube, in sequence, vortexing after the addition of each reagent: 3ml 5M HCl;
0.5ml 0.2% (w/v) sodium nitrite; 0.5ml 1% (w/v) ammonium sulphamate; 0.5ml 0.2%
(w/v) naphthylenediamine dihydrochloride. Samples were then allowed to stand for
45 minutes to allow colour development. Absorbance of each sample at 540nm was
measured (in triplicate) using a Camspec double beam spectrophotometer.
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A standard curve was plotted from the average absorbance of each of the PABA
standard samples. The equation of the line of the standard graph was used to calculate
the PABA concentration in each urine sample from the average absorbance of the
three tubes. PABA recovery in mg/litre was multiplied by 24-hour urine volume,
giving recovery in mg/24h which was then expressed as a percentage of the original
240mg ingested. Urine collections with PABA recovery greater than 85% were
deemed sufficiently complete for further analysis.
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Analytical Methodology
Background
Separation and analysis of phytoestrogenic compounds followed the discovery of
oestrogenic activity in food and plant extracts. With the introduction of increasingly
sensitive technologies phytoestrogen analysis has advanced considerably. However,
the isolation and quantification of phytoestrogens is considered particularly difficult
even with today’s technology, due to the similarity of their structures and chemical
properties and the structural and chemical similarity of PE to other compounds in the
complex biological matrices in which they occur. (COT, 2003b)
The predominant analytical methods in current use are: gas chromatography with
mass spectrometric detection (GC-MS); liquid chromatography with mass
spectrometric detection (LC-MS); high-performance liquid chromatography with
ultraviolet detection (HPLC-UV) and fluorescent- or radio-immunoassays (FIA or
RIA).
GC-MS is sufficiently sensitive to measure concentrations of PE of less than parts per
million (COT 2003b & refs. therein), the exact limits of sensitivity depending on the
laboratory. However, PE require transformation to trimethylsilyl derivatives to attain
sufficient volatility for gas chromatographic analysis. This adds considerably to the
time and expense of sample preparation.
LC-MS allows equal sensitivity of detection but without the necessity for
derivatisation prior to analysis. Thus, LC-MS has the potential to be used for non-
destructive analysis of PE glycosides and glucuronide/sulphate conjugates but this is
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not yet commonplace due to the expense of obtaining suitable internal standards
(COT 2003b).
The great advantage of GC-MS and LC-MS technologies is that they enable the use of
isotopically labelled internal standards, chemically identical to the PE of interest but
distinguishable by MS. This allows definitive identification of the compound of
interest in the chromatogram and permits quantification of PE relative to a known
amount of the isotopically labelled internal standard, thus correcting for losses in
sample preparation. 13C labelled compounds are the standards of choice, being
considerably more stable during analysis than the alternative deuterium (2H) labels.
(COT 2003b)
HPLC-UV allows rapid, simultaneous purification and quantification of complex
mixtures but with a higher and more variable limit of detection than mass
spectrometric techniques. UV detection does not permit the use of isotopically
labelled internal standards, so quantification is based on comparisons with calibration
curves derived from reference standards of the analytes. This does not correct for
losses during sample preparation and may also lead to inaccurate measurements of the
analyte due to co-elution in the sample with substances not present in the reference
standard (COT 2003b).
Immunoassays employ antibodies raised against PE aglycones and quantification is
achieved by using radiolabelled or fluorescently labelled PE in competitive assays.
This is cheaper, faster and less time-consuming than GC-MS or LC-MS but is less
specific. The antibodies raised against daidzein and genistein may cross-react with
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other PE or with other similar compounds such as steroids in biological samples.
(COT 2003b)
LC-MS was chosen for this study because of its high sensitivity and specificity, the
relative ease of sample preparation by comparison with GC-MS and the availability of
internal standards.
Prior to quantification, PE must first be extracted from the matrix (blood or urine
samples in this study). Because this process is not 100% efficient, the internal
standard is added to the sample prior to extraction to enable determination of the
relative concentration of PE analyte to a known concentration of internal standard.
In urine and blood, PE are present predominantly as conjugates, bound to glucuronide
or sulphate residues (Hendrich, 2002). The proportion of free PE is very low and very
difficult to detect with the required degree of accuracy, so enzymatic hydrolysis is
used to cleave PE from their conjugating groups and enable quantification of the ‘total
PE’ content of the sample. When investigating relationships between intake and
blood or urine concentrations of PE it is necessary to use total PE measurements
because it is not known whether the proportion of free to bound PE alters with
increasing dose. Measurement of PE glucuronides and sulphates is now possible with
LCMS technology but requires labelled PE glucuronide/sulphate internal standards
which are not yet readily available. As this study was intended to develop a
biomarker that would be widely applicable in clinical and epidemiological studies, it
was decided to measure total PE concentration, employing mass-labelled daidzein and
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genistein in the unconjugated forms as internal standards so that the method can be
more easily replicated in other laboratories.
After hydrolysis and extraction, PE are separated from chemically similar constituents
of the biological matrix (such as steroids in the case of urine and blood samples) in a
process referred to as sample ‘clean-up’ or preparative chromatography. The
narrower spectrum chemical extract which results from this process is then separated
and its components quantified. Sample clean-up eliminates the majority of
contaminants which might foul the analytical column, impairing its capacity to
separate PE with consistent retention times and discrete peaks, and eliminates some
contaminants with the same mass as a compound of interest which would create an
artefactual peak in the mass chromatogram.
Some laboratories have employed ready-made solid-phase extraction cartridges to
simplify sample clean-up but in this study, less-expensive glass columns packed with
LH-20 lipophilic sephadex were used.
The sequence of PE extraction and analysis is depicted in Figure 2.
Methods
56
Figure 2: Sequence of PE extraction and analysis
Biological sample
Addition of
internal standard
Enzymatic
hydrolysis
Extraction with
organic solvent
Preparative
chromatography
Chromatographic
separation
Detection and
quantification
Sample
preparation
analysis
Methods
57
Sample preparation
Chemicals and reagents:
Methanol, HPLC grade
Chloroform, HPLC grade
Heptane, HPLC grade
Ethyl acetate, Analar grade
Sephadex LH-20 bead size 25-100μ
Β-glucuronidase with sulphatase from Helix pomatia type H-3AF; 127,000 units/ml
(one unit will liberate 1μg phenolpthalien from phenolpthalien glucuronide per hour at
37oC and pH 5.0)
Sodium acetate buffer 0.1M acidified to pH 5.0 using glacial acetic acid.
All reagents were purchased from Sigma unless otherwise stated.
Analytes:
Daidzein (7,4’-dihydroxyisoflavone), genistein (5,7,4’-trihydroxyisoflavone), equol
(7,4’dihydroxyisoflavane) and triply 13C-labelled internal standards of genistein and
daidzein were a gift from Dr M. Morton, Cardiff University, Wales.
A working dilution of PE analytes was prepared in methanol in a volumetric flask to
give a concentration of 250ng/ml. This was used as an external standard in
preparation of the calibration curves.
Similarly, a methanolic solution of 13C PE was prepared to a concentration of
250ng/50μL. 50μL of this solution was added to each sample and to each calibration
standard. Methanolic stock solutions were stored in a refrigerator at 4oC.
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All glassware was silanised prior to use according to the method of Pumford et al.
(2002). Briefly, glassware was soaked in a solution of 3% dichlorodimethylsilane in
toluene for five minutes then rinsed once with toluene, twice with methanol and air
dried in a fume cupboard.
Hydrolysis and Extraction
Urine and plasma samples were prepared according to the method of Pumford et al.
(2002) and Morton et al. (2002) but omitting the derivatisation step.
Plasma and urine samples were defrosted fully and shaken before aliquotting. Aliquot
volume taken was adjusted according to supplementation phase and sample matrix to
ensure that the final concentration of PE in the prepared sample would fall within the
range which produces a reliable, linear response from the analytical method. For all
blood samples, aliquots of 500μL were used. For baseline and placebo urine samples,
250μL aliquots, for urine samples during 55mg/d supplementation 50μL aliquots, for
urine samples during 110mg/d supplementation 40μL aliquots and for urine samples
during 165mg/d supplementation 25μL aliquots were taken. If, after LC-MS analysis,
the concentration of PE was found to be outside the calibrated linear range then
sample preparation was repeated with a smaller volume of urine or blood.
Aliquots of plasma or urine were pipetted into labelled, ground-glass stoppered
boiling tubes (Quickfit NS19/26) and the weight of the aliquot recorded.
β-glucuronidase/sulphatase was mixed with 5ml sodium acetate buffer in a test tube
and divided among the samples allowing 1000units phenolpthalien-liberating activity
per sample. A further 3ml sodium acetate buffer was added to each sample.
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50μL of the internal standard cocktail was added to each sample using a 50μL glass
syringe. Internal standard solution was allowed to equilibrate to room temperature for
at least one hour before use. Samples were then vortexed and incubated in a water
bath at 37oC for 16 hours. After hydrolysis, samples were cooled and PE extracted by
adding 4ml ethyl acetate to each tube. Samples were shaken for 1 minute and placed
in a salt-ice bath to freeze the aqueous layer before decanting the organic layer into
labelled test tubes. A further 4ml ethyl acetate was added to each sample and the
extraction repeated, adding the second aliquot of ethyl acetate to the first. The test
tubes were then evaporated to dryness in a Techne dri-block at 60oC under a gentle
stream of nitrogen.
Preparative Chromatography
Columns were prepared by cutting the tips from glass Pasteur pipettes to widen the
opening and rounding the sharp edges in a Bunsen flame. Columns were then
silanised following the procedure above, marked at 3.5cm from the neck and plugged
with silanised glass wool. Supported in a rack and draining into waste-collecting
tubes, the columns were packed with LH-20 lipophilic Sephadex to the 3.5cm mark.
350mg Sephadex per sample was required and the total quantity of Sephadex was
soaked for approximately 15 minutes in of 50ml solvent mixture (10 parts chloroform,
10 parts heptane, 1 part methanol) to form a gel.
The dry extract from each sample was dissolved in 200μL of the same solvent mixture
with vortexing, and transferred to the top of each correspondingly numbered column.
A further 200μL solvent mixture was added and the washings again transferred to the
top of the column. Samples were then washed onto the column with 3x 1ml plus 1x
0.6ml aliquots of solvent mixture, running each addition down the side of the glass to
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avoid disturbing the surface of the Sephadex. The solvent mixture was discarded and
PE eluted from the columns into clean, numbered, silanised test tubes with 4x 1ml
aliquots of methanol. Methanol was evaporated from the samples under nitrogen at
60oC and the samples re-dissolved in 80μL 50% v/v methanol/water before being
transferred to silanised inserts in autosampler vials for LC-MS.
Preparation of Calibration Curve
Calibration standards were prepared using the methanolic stock solutions of labelled
and unlabelled phytoestrogen standards as described previously. A different volume
of unlabelled analyte solution was added to each vial with a constant volume of
internal standard solution (volumes and the corresponding weights and concentrations
of standard solutions are given in Table 5). The methanolic solutions in the vials were
blown to dryness under nitrogen at 60oC and the solid residue re-dissolved in 80μL of
50% v/v methanol/water and transferred to silanised inserts in the same manner as the
prepared samples. A set of calibration standards was analysed with each batch of
samples.
Table 5: Calibration Standards
Volume of
internal
standard
(μL)
Mass of
internal
standard
(ng)
Concentration
of internal
standard
(ng/ml)
Volume of
unlabelled
analyte
(μL)
Mass of
unlabelled
analyte
(ng)
Concentration
of unlabelled
analyte
(ng/ml)
50 250 3125 0 0 0
50 250 3125 200 50 625
50 250 3125 400 100 1250
50 250 3125 800 200 2500
50 250 3125 1000 250 3125
50 250 3125 1200 300 3750
50 250 3125 2000 500 6250
50 250 3125 4000 1000 12500
50 250 3125 8000 2000 25000
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Liquid Chromatography
5μL injections of each sample were taken by an autosampler (Waters 2795
Separations Module) and separated on a reversed-phase, polar end-capped C18
column (Phenomenex Synergi HydroRP) preceded by two polar end-capped C18
guard cartridges (Phenomenex). The autosampler, LC and MS were controlled by
MassLynxTM software (MassLynx Version 4.0 © Micromass Ltd 2002).
A flow rate of 0.22ml/min was used and the mobile phases were:
A. Water with 30ml 40mM ammonium acetate
B. 90% methanol, 10% water with 30ml 40mM ammonium acetate
Run time for each sample was 26 minutes with a gradient of 100% A to 100% B over
10 minutes followed by isocratic elution of analytes at 100% B for 10 minutes.
Mobile phase was returned to 100% A over 0.5 min and the column re-equilibrated at
100% A for 5.5 min before injecting the next sample. The retention time of daidzein
was 11.50-12.12 minutes and of genistein 12.10-13.02 minutes. Retention time was
consistent within each batch of samples but varied slightly from day to day.
Before sample analysis the column was equilibrated using 100% A at 0.22ml/min for
30min to remove the storage solvent and establish operating conditions. Each run was
started with a blank (injection of 5μL methanol) followed by reference standards to
confirm correct operating conditions. A set of calibration standards (prepared as
described above) were analysed with each batch of samples to verify the relationship
between the absolute concentration of analyte and the response of unlabelled analyte
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relative to internal standard. Calibration standards were interspersed throughout the
sample list to confirm consistent performance throughout the run. Every third or
fourth injection was a blank, used to ensure that peaks measured in samples were not
artefacts or contaminants and also to remove strongly retained compounds which were
not entirely eluted during the 10min isocratic gradient, preventing fouling of the
column. After each batch of samples the column and guard cartridges were flushed
with 5 column volumes of 100% water to remove buffer, then the column was flushed
with 98% methanol/water (without buffer) at 0.2ml/min for 40-60 minutes to remove
strongly retained contaminants. Guard cartridges were visually inspected after each
run, replaced if soiled and if apparently clean, flushed with 98% methanol/water at
0.2ml/min for 10 minutes. Both column and guard cartridges were then washed with
5 column volumes 65% acetonitrile/ 35% water (storage solvent) and capped to
prevent dessication during storage.
Mass Spectrometry
A Micromass LCT orthogonal acceleration time-of-flight mass spectrometer was
employed for detection, identification and quantification of compounds.
The column effluent was introduced into the electrospray ionisation (ESI) interface
where nitrogen gas was used to desolvate ions at 300oC. In ESI, an aerosol of charged
droplets is produced by applying a strong electrical charge to the eluent as it emerges
from the nebuliser. As the solvent evaporates, these charged droplets reduce in size
until they are sufficiently charge-dense to eject sample ions from the surface of the
droplet (the Rayleigh limit). At this point a "Coulombic explosion" occurs and the
droplet is ripped apart. This produces smaller droplets that can repeat the process as
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well as naked charged analyte molecules. Charged analyte molecules (they are not,
strictly speaking, ions) are then drawn through the sample cone aperture into the ion
block before being extracted into the analyser. ESI was employed because it permits
the analysis of intact molecules at high accuracy. It is a ‘soft’ ionisation method since
the sample is ionised by the removal of a proton, with very little extra energy
remaining to cause fragmentation of the sample ions, and is well-suited to the analysis
of polar molecules ranging from less than 100 Da to more than 1,000,000 Da in
molecular mass (Ashcroft, 2006). Figure 3 is a schematic of the ESI interface.
Figure 3: Electrospray ionisation interface
Ions generated in the Z-spray source are transferred to the orthogonal time-of-flight
analyser via the two RF lenses. Ions are then focused onto the pusher by the
acceleration, focus, steer and tube lenses. The pusher pulses a section of the beam
towards the reflectron, which then reflects ions back to the detector. Ions with the
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highest mass to charge ratio (m/z) have a longer flight time between the pusher and
detector, so ions are separated in mass. TOF MS performs parallel detection of all
masses within the spectrum simultaneously at very high sensitivity and acquisition
rates, allowing each spectrum to be representative of the eluent composition at that
point in time even with high chromatographic flow rates. Figure 4 shows a schematic
of the ion optical system.
Figure 4: Ion optics
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The TOF MS was operated in negative ion mode, with capillary voltage 2900V,
extraction cone voltage 3V to minimise ion fragmentation with this low molecular
weight sample, and sample cone voltage 25V - a value towards the lower end of the
operating range since small molecules were being analysed (larger cone voltages
increase ion fragmentation within the source). Source temperature was 100oC and the
RF lens was set to 250, since standard appropriate settings are 300 for compounds
200-500Da and 200 for compounds <200Da.
Compounds were quantified using a specific quantify method file created in
MassLynx. Mass-to-charge ratios and retention times for the compounds of interest
were specified and internal standards identified in the quantify method file. For
unlabelled analytes, retention time was set equal to that of the relevant internal
standard.
Chromatograms were smoothed by the Savitzky-Golay method, using a smoothing
window size of 5 (selected by dragging across a peak at half height) and a magnitude
of 2 smooths.
Peak detection and integration parameters were left at default values and each peak
manually integrated after running the automated quantify method. Responses were
based on peak area and a report of the peak areas for each compound in each sample
was saved and printed after manual integration.
Analysis of data
The relative response ratio for each analyte was determined by;
Relative response ratio (RRR) = analyte peak area ÷ internal standard peak area
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Calibration standards were constructed in MS Excel by plotting RRR for each analyte
against the known mass of that analyte present in the standard vial. Linear regression
was performed on these points and the equation of the line used to interpolate samples
according to their RRR. Each batch of samples was quantified according to the linear
regression of the calibration standards analysed on the same day, so each batch was
calculated by a different equation of the form:
Genistein concentration in sample (ng/g) = (mRRR + c) ÷ a
Daidzein concentration in sample (ng/g) = (m1RRR1 + c1) ÷ a
Where m = gradient of linear regression through genistein calibration points
m1 = gradient of linear regression through daidzein calibration points
RRR = response ratio of genistein relative to 13C3-genistein
RRR1 = response ratio of daidzein relative to 13C3-daidzein
c = intercept of genistein linear regression with y-axis
c1 = intercept of daidzein linear regression with y-axis
a = weight of aliquot of urine/blood sample in grams
For 24-hour urine samples, the concentration of each isoflavone was multiplied by the
total collection volume in millilitres to give the isoflavone excretion in ng/24hours.
Statistical analysis was performed using Microsoft Excel® and the results are
presented in Chapter 4.
A number of procedures were employed to ensure the validity and repeatability of the
results obtained by the methods outlined above. These procedures are described in
Chapter 3.
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ACCURACY, VALIDITY AND REPEATABILITY
Conducting the study
A number of measures were employed to ensure that data obtained during the study
was accurate. At each visit, participants were asked whether they had remembered to
take all of the study supplements at the correct time. Urine collections were validated
by PABA recovery to ensure that incomplete urine collections were not taken to be
reliable samples for isoflavone analysis. The 17 samples which were deemed to be
invalid collections are shown in Appendix 13.
All data which were entered into electronic files during the study were later checked.
Dietary analysis:
Dietary records were verified with volunteers to ensure that no meal had been omitted
from the record and that portion sizes were recorded. To assist the volunteers with
accurate recording, full instructions for recording portion sizes were included in every
food diary. Daily caloric intake was compared with basal energy requirements and
participants weighed at the beginning and end of the study to give an indication of
whether normal, sufficient dietary intake had been maintained.
The database used to assign isoflavone values to foods has been validated for this
purpose in a previous study using duplicate diet analysis (Ritchie et al., 2005).
During each supplement phase, each participant provided two spot urine samples and
two blood samples, one pair of samples after taking the supplement for three days
(blood 1 and urine 1) and one pair of samples after taking the supplement for seven
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days (blood 2 and urine 2). Blood and urine 1 corresponded to a 24-hour recall of
dietary intake while blood and urine 2 were taken during the two-day food diary
period. Due to the expense of analysing the urine samples, only some of the urine 1
samples were analysed. Urine 2 during each phase was analysed for every
participant. Eighteen of the urine 1 samples were compared with urine 2 samples for
the same participant using a paired t-test. No significant difference was found
between spot urine isoflavone concentration after taking the supplement for three days
and urine concentration after taking the supplement for seven days (p = 0.1995). All
of the spot urine 1 samples are compared with all of the spot urine 2 samples in
Figure 5.
Figure 5:
Comparison between spot urine 1 and spot urine 2
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It was not possible to obtain a blood sample from every participant at every visit due
to difficulties with phlebotomy. Therefore, some of blood sample 1 and some of
sample 2 were included in the analysis to provide one blood sample per sample phase,
per participant. Blood 1 samples were compared with blood 2 samples using a
homoscedastic t-test and no significant difference was found between plasma
concentration of isoflavones after three days and after seven days of supplementation
(n = 75; p = 0.5811). Pairs of blood samples where both blood 1 and blood 2 were
obtained for the same participant were compared using a paired t-test, and again no
significant differences were found (n = 6 pairs; p = 0.7119). All of the blood 1
samples are compared with all of the blood 2 samples in Figure 6.
Figure 6:
Comparison between blood 1 and blood 2
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Analytical method:
Calibration
Calibration standards were prepared as previously described and included in every
run. The concentration of isoflavones present in samples was calculated using the
equation of the line of the calibration curve from that same run. This was carried out
in order to control for variations in system performance from day to day. However,
all calibration points were subsequently plotted on the same graph and shown to fall
on the same line (Figure 7). Figure 7 demonstrates that response of the detector was
linear in the range of relative response ratios 0 to 10, so the volume of urine/blood
sample prepared was adjusted to give a relative response ratio within this range.
Figure 7:
all calibration points
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The calibration curves for each run were made up in 50% v/v methanol:water for ease
of preparation but were compared with a calibration curve made using a urine sample
spiked with unlabelled isoflavones and prepared in an identical manner to the study
samples. The resulting calibration curve was superimposed with the curves generated
by calibration standards in 50% methanol.
Figure 8:
comparison between calibration standards in urine and in methanol
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Limits of detection and quantification
The limit of detection was defined as the concentration of isoflavone which produced
peaks with a signal-to-noise ratio (s/n) >2. A control urine sample divided into 250uL
aliquots and the aliquots spiked with six different concentrations of genistein and
daidzein and a constant amount of 13C3 genistein and daidzein (250ng).
Signal-to-noise ratios for these spiked urine samples are given in Table 6.
Table 6: Signal-to-noise ratios
Concentration of added
genistein/daidzein (ng/ml)
s/n genistein s/n daidzein
5 2.17 0.75
10 3.40 2.12
15 3.10 2.17
20 2.78 2.00
25 3.25 3.44
50 2.89 3.67
Thus, the lower limit of detection (LOD) for genistein was defined as 5ng/ml and the
lower limit of detection for daidzein was defined as 10ng/ml.
Percentage genistein and daidzein recovery close to the LOD were used to assess the
lower limit of quantification and are shown in Table 7.
Table 7: Percentage recovery close to the limits of detection
Concentration of added
genistein/daidzein (ng/ml)
% genistein recovered % daidzein recovered
5 134 94
10 103 99
15 106 96
20 98 96
25 103 106
50 94 91
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The lower limit of quantification (LOQ) was defined as the concentration, greater
than the LOD, at which genistein or daidzein recovery was between 90%-110%.
Thus, the LOQ for genistein was 10ng/ml for each analyte. This compared
favourably with the limits of detection reported in other studies (Atkinson et al., 2002;
Bloedon et al., 2002; Ritchie et al., 2004). Since intake was compared with total
genistein plus daidzein concentrations in blood and urine, the LOQ for genistein +
daidzein was deemed to be 20ng/ml. Concentrations lower than 20ng/ml were
averaged to 50% of the LOQ (ie 10ng/ml) for the purposes of calculating the
correlation with intake.
The limit of detection of analytes from urine samples was extrapolated to blood
samples. This was because insufficient plasma was obtained from any one individual
to prepare a set of spiked samples as was carried out with urine samples.
Because the signal-to-noise ratio is the primary determinant of the lower limit of
detection, the analytical method was designed to maximise the signal-to-noise ratio,
thus lowering the limit of detection. The use of isotopically labelled internal
standards allows individual mass chromatograms to be examined which dramatically
reduces noise in itself. The extensive sample cleanup method was employed to
minimise the ‘background’ in chromatograms. Other measures to reduce
chromatographic noise were:
 placement of the column in a column heater at 23oC to protect it from
temperature fluctuations.
 using only HPLC-grade filtered and de-gassed solvents.
 mixing mobile phase B in the solvent reservoir rather than mixing online
during isocratic elution.
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 interspersing analytical samples with blank injections of 100% methanol to
prevent build-up of contaminants on the column during the run.
 flushing of the column for one hour with 98% methanol at the end of each
overnight run.
To obtain maximum signal, the injection volume was optimised to give large analyte
peaks while still being less than half the injection volume required to produce
symptoms of column overload (such as peak spreading, fronting or splitting) (Dolan,
2006).
Internal Standard:
The use of 13C3-labelled internal standards enabled definitive identification of analytes
by matching retention time. The internal standard (IS) also allowed correction for
losses of analyte in sample preparation, since both analyte and IS behave identically
and it can be presumed that losses of IS and unlabelled analyte will be proportionally
identical, analytes are quantified relative to the internal standards. Percentage
recovery of IS can be used to determine the degree of losses in sample preparation.
Intra-assay coefficient of variation
The intra-assay coefficient of variation (sometimes referred to as percent relative
standard deviation or %RSD) is an expression of the degree of inaccuracy in
measurement of samples, prepared in multiples and analysed in the same run on the
same day. For bioanalytical LC-MS such as the determination of pharmacologically
active substances in blood and urine, 15-20% imprecision and inaccuracy (ie
coefficients of variation between 15 and 20) are generally accepted due to relatively
low concentrations of the analytes and the large background from a biological matrix
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(Dolan, 2006). Other authorities consider a coefficient of variation less than 10% to
be preferable. The intra-assay coefficients of variation (CV) for this study are given
in Table 8.
Table 8: Intra-assay coefficients of variation
Sample Genistein + Daidzein
(ng/ml)
Coefficient of
variation (%)
Machine
IS6 baseline spot
urine
3180.95
4449.69
3276.03
3662.13
13.72 SCRI (Scottish Crop
Research Institute,
Invergowrie)
IS72 110mg/d spot
urine 1
14243.43
13784.34
13046.37
13315.16
3.36 SCRI
IS71 baseline spot
urine
4364.57
4789.39
4.64 SCRI
IS70 55mg/d blood
2
530.90
519.92
1.05 SCRI
IS64 55mg/d blood
1
1466.30
1094.54
1122.22
13.77 SCRI
IS71 55mg/d 24hU
(17/10/05)
7320.49
7026.57
2.03 SCRI
IS71 55mg/d 24hU
(13/10/05)
6584.85
7114.09
6878.08
8291.57
8.98 SCRI
IS71 55mg/d 24hU
(12/9/05)
6185.56
6586.34
7041.18
5.29 SCRI
IS71 55mg/d 24hU
(9/6/06)
8197.83
9467.76
7.19 BMS (biomolecular
sciences St Andrews)
IS66 55mg/d 24hU 6195.65
5964.54
1.90 BMS
IS71 55mg/d 24hU 8876.77
8368.27
8427.55
2.65 BMS
IS70 165mg/d 24hU 24205.48
22934.35
19615.61
8.70 BMS
IS24 110mg/d spot
urine 2
163395.71
153763.58
3.04 BMS
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The mean intra-assay coefficient of variation for samples run at SCRI was 6.61%
(range 1.05-13.77%) and for samples run at BMS was 4.70% (range 1.90-8.70%).
Inter-assay coefficient of variation
The inter-assay coefficient of variation is an expression of the degree of inaccuracy in
measurement of analytes when samples are prepared and analysed on different days
by the same method. Again, a coefficient of variation between 15 and 20% is
acceptable but less than 10% is preferable. In this study, the inter-assay coefficient of
variation was assessed for each machine and the values for both machines combined
to determine the percentage inaccuracy over the entire set of analyses. The results are
given in Table 9.
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Table 9: Inter-assay coefficients of variation
Sample Genistein + Daidzein
(ng/ml)
Coefficient of
variation (%)
Machine
IS71 50mg/d 24hU 6185.56
6586.34
7041.18
6584.85
7114.09
6878.08
8291.57
7320.49
7026.57
7.98 SCRI
IS71 50mg/d 24hU 8967.77
9003.29
7997.99
8197.83
9467.76
8980.75
8713.85
8876.77
8368.27
8427.55
4.87 BMS
IS71 50mg/d 24hu 6185.56
6586.34
7041.18
6584.85
7114.09
6878.08
8291.57
7320.49
7026.57
8967.77
9003.29
7997.99
8197.83
9467.76
8980.75
8713.85
8876.77
8368.27
8427.55
12.41 SCRI and
BMS
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Thus, the degree of imprecision between assays at SCRI was 7.97% and at BMS was
4.87%. By analysing the same sample multiply on both machines it was
demonstrated that inter-assay imprecision was 12.41%, which falls within the
acceptable range defined above.
Inter- and intra-assay coefficients of variation observed were comparable with the
precision seen in previous studies of isoflavone concentration in biological matrices
(Atkinson et al., 2002; Holder et al., 1999; Hutchins et al., 1995; Karr et al., 1997;
Watanabe et al., 1998).
The methods employed in data collection for this study were therefore deemed to be
sufficiently repeatable, valid and accurate to produce reliable results.
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RESULTS
Introduction
The primary aim of this study was to validate 24-hour urine, timed plasma and spot
urine samples as reliable measures of isoflavones intakes <165mg/d. A secondary
aim was to determine whether plasma concentration or urinary excretion reaches a
plateau at this level of intake.
Data from 31 participants (11 male, 20 female) were analysed. Scatter plots of the
relationship between intake and each biomarker are presented for both non-
transformed and log-transformed data. Relationships and agreement between the
biomarkers are described. Percentage urinary recovery and percentage of dose
appearing in plasma were plotted against dose to determine the linearity of dose
response for this intake range. The effect of age and gender on biomarkers of intake
was also explored.
Participant demographics
The mean age of participants was 29 years (range 18-60 years). Participant
demographic data are shown in Table 10.
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Table 10: Participant demographics
ID Code Gender Age Height (m) Weight at
start (kg)
Weight at
end (kg)
BMI at start
is 1 M 19 1.82 104 106 31.40
is 4 F 19 1.62 46 46 17.53
is 5 F 19 1.56 60 60 24.65
is 6 M 18 1.86 110 113 31.80
is 9 F 19 1.57 60 59 24.34
is 15 F 21 1.74 67 69 22.13
is 17 F 21 1.70 76 77 26.30
is 18 M 21 1.82 76 78 22.94
is 23 M 21 1.82 88 86 26.57
is 24 F 20 1.74 57 56 18.83
is 25 F 23 1.61 75 75 28.93
is 26 M 21 1.86 96 96 27.75
is 27 F 19 1.56 64 62 26.30
is 28 M 20 1.87 98 100 28.02
is 35 F 20 1.79 68 66 21.22
is 40 F 19 1.70 67 67 23.18
is 42 F 27 1.73 85 85 28.40
is 44 F 21 1.78 60 60 18.90
is 48 M 18 1.79 81 81 25.28
is 56 F 55 1.61 74 73 28.55
is 57 F 57 1.57 53 52 21.50
is 59 F 60 1.62 64 61 24.39
is 61 F 35 1.62 67 67 25.53
is 63 M 23 1.78 99 100 31.25
is 64 F 22 1.57 51 51 20.69
is 66 M 56 1.75 80 80 26.12
is 67 F 43 1.50 54 55 24.00
is 68 M 49 1.79 88 90 27.46
is 70 F 28 1.55 59 59 24.56
is 71 F 56 1.62 70 67 26.67
is 72 M 26 1.85 73 74 21.33
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RELATIONSHIPS BETWEEN INTAKE AND BIOMARKERS
Each individual participant’s dietary intake of isoflavones was added to his or her
supplemental intake and scatter plots of total intake against plasma and urinary
isoflavones were produced. Linear regression was performed on the scatter plots and
the equations of these lines are displayed on Figures 9 to 12 along with Pearson’s
correlation coefficient (r2).
Figure 9:
relationship between isoflavone intake and urinary excretion over 24
hours
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Figure 10:
Relationship between isoflavone intake and excretion in spot urine samples
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The three outliers with higher than expected isoflavone concentration in spot urine
samples belonged to two female subjects who had a low fluid intake and passed small
volumes of urine over 24 hours. These three spot urine samples were visibly darker
and more concentrated than the other spot urine samples. Re-plotting the relationship
between intake and spot urine concentration excluding these three samples gave the
relationship shown in Figure 11.
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Figure 11:
Relationship between isoflavone intake and excretion in spot urine
samples - excluding outliers
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Figure 12:
Relationship between isoflavone intake and concentration in
plasma samples
y = 1E-05x + 0.0613
R2 = 0.605
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Relationship between isoflavone intake and excretion in spot urine
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Because it was hypothesised that the relationship between intake and excretion would
not be perfectly linear, data on both axes were log transformed (log10) and plotted
again in Figures 13 to 15 to clarify the relationship between intake and excretion.
Figure 13:
Relationship between log intake and log 24h urinary excretion
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Figure 14:
Relationship between log isoflavone intake and log isoflavone
excretion in spot urine samples
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R2 = 0.6862
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Figure 15:
Relationship between log isoflavone intake and log plasma isoflavone
concentration
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n = 100 samples from 30 volunteers; p < 0.001
Larger values of r2 for log transformed data indicate that this model is a better fit. The
equations of linear regressions on log-log graphs were therefore used to define the
relationship between intake and excretion or plasma concentration of isoflavones.
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For 24-hour urine samples:
Y = mX + c
Y = 0.7421X + 0.8216
Where Y= log10(isoflavone excretion in μg/24h) and isoflavone excretion = y
X= log10(isoflavone intake in μg/24h) and isoflavone intake = x
Therefore;
log y = 0.7421(log x) + 0.8216
c = 0.8216 which is a logarithm of a constant, k
0.8216 = log10k [c = log k ≡ k = 10c]
k = 100.8216
log y = 0.7421(log x) + log100.8216
log y = 0.7421(log x) + log6.63132
log y = log(x0.7421) + log6.63132 [n(log x) = log xn]
log y = log6.63132(x0.7421) [log a + log b = log (ab)]
y = 6.63132x0.7421
where y = isoflavone excretion in μg/24h
and x = isoflavone intake in μg/24h
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For spot urine samples:
Y = mX + c
Y = 0.8009X -2.692
Where Y= log10(isoflavone excretion in μg/ml) and isoflavone excretion = y
X= log10(isoflavone intake in μg/24h) and isoflavone intake = x
Therefore;
log y = 0.8009(log x) – 2.692
c = -2.692 which is a logarithm of a constant, k
-2.692 = log10k [c = log k ≡ k = 10c]
k = 10-2.692
log y = 0.8009(log x) + log10-2.692
log y = 0.8009(log x) + log0.002032357
log y = log(x0.8009) + log0.002032357 [n(log x) = log xn]
log y = log 0.002032357(x0.8009) [log a + log b = log (ab)]
y = (2.0324x10-3)x0.8009
where y = isoflavone excretion in μg/ml
and x = isoflavone intake in μg/24h
The outliers in spot urine concentration were included when deriving this equation
since it is to be expected that spot urine samples will vary in their absolute
concentration and therefore also in their isoflavone concentration. It was considered
that exclusion of these outliers would unjustifiably bias the equation derived.
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For plasma samples:
Y = mX + c
Y = 0.4889X -2.4744
Where Y= log10(plasma isoflavone in μg/ml) and plasma isoflavone = y
X= log10(isoflavone intake in μg/24h) and isoflavone intake = x
Therefore;
log y = 0.4889(log x) – 2.4744
c = -2.4744 which is a logarithm of a constant, k
-2.4744 = log10k [c = log k ≡ k = 10c]
k = 10-2.4744
log y = 0.4889(log x) + log10-2.4744
log y = 0.4889(log x) + log0.003354285
log y = log(x0.4889) + log0.003354285 [n(log x) = log xn]
log y = log 0.003354285(x0.4889) [log a + log b = log (ab)]
y = (3.3543x10-3)x0.4889
where y = plasma isoflavone in μg/ml
and x = isoflavone intake in μg/24h
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Statistical Significance
Statistical significance of the correlation between intake and biomarkers was assessed
by a student’s t-test using the following equation:
t = r x √ n-2
1-r2
The value of p for each corresponding value of t was determined from t-tables.
Therefore, for the correlation between isoflavone intake and 24hU excretion:
r2 = 0.8665; n = 109
t = (√0.8665) x √(107 ÷ 0.1335)
= 0.930859817 x √801.498127
= 0.930859817 x 28.31074226
t = 26.3533
p < 0.001
For the correlation between isoflavone intake and spot urine isoflavone concentration:
r2 = 0.6862; n = 143
t = (√0.6862) x √(141 ÷ 0.3138)
= 0.828371897 x √449.3307839
= 0.828371897 x 21.19742399
t = 17.5593
p < 0.001
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For the correlation between isoflavone intake and plasma isoflavone concentration:
r2 = 0.6113; n = 100
t = (√0.6113) x √(98 ÷ 0.3887)
= 0.781856764 x √252.1224595
= 0.781856764 x 15.87836451
t = 12.4146
p < 0.001
Results
91
CALCULATING INTAKE FROM CONCENTRATION IN BIOLOGICAL
FLUIDS
In this study, the independent variable was isoflavone intake, since this was
manipulated by giving oral isoflavone supplements. However, biomarkers of
isoflavone exposure may also be used to infer intake from a measured plasma
concentration or measured excretion. Therefore, equations relating intake to
biomarkers were re-arranged to allow intake to be calculated from a known
concentration in biological fluids.
For 24-hour urines:
y = 6.63132x0.7421
therefore 6.63132x0.7421 = y
x0.7421 = y ÷ 6.63132
x = 0.7421√( y ÷ 6.63132)
≡ x = (y ÷ 6.63132)1.3475
where y = isoflavone excretion in μg/24h
and x = isoflavone intake in μg/24h
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For spot urine samples:
y = (2.0324x10-3)x0.8009
therefore (2.0324x10-3)x0.8009 = y
x0.8009 = y ÷ 2.0324x10-3
x = 0.8009√( y ÷ 2.0324x10-3)
≡ x = (y ÷ 2.0324x10-3)1.2486
where y = isoflavone excretion in μg/ml
and x = isoflavone intake in μg/24h
For plasma samples:
y = (3.3543x10-3)x0.4889
therefore (3.3543x10-3)x0.4889 = y
x0.4889 = y ÷ 3.3543x10-3
x = 0.4889√( y ÷ 3.3543x10-3)
≡ x = (y ÷ 3.3543x10-3)2.0454
where y = plasma isoflavone in μg/ml
and x = isoflavone intake in μg/24h
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The correlation between the three biomarkers of isoflavone exposure was also
assessed and log-log graphs with correlation coefficients are shown in Figures 16 to
18. Outliers in spot urine concentration were included.
Figure 16:
Correlation between log 24hu excretion and log plasma
concentration
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Figure 17:
Correlation between log 24hu excretion and log spot urine
concentration
y = 1.0736x - 3.4337
R2 = 0.8373
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Figure 18:
Correlation between log plasma concentration and log spot urine
concentration
y = 1.5574x + 1.4125
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LINEARITY OF DOSE RESPONSE
To determine whether plasma isoflavone concentrations or urinary isoflavone
concentrations during isoflavone supplementation <165mg/d appeared linear, mean
isoflavone excretion in 24-hour urine samples, spot urine samples and plasma samples
taken during each intervention phase are depicted in Figures 19 to 22.
Figure 19:
Isoflavone excretion during each supplement phase
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Figure 20:
isoflavone concentration in spot urine samples during each
supplement phase
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Isoflavone concentration in spot urines apparently reached a maximum at an intake of
110mg/d but when the three outliers previously identified (IS64 during 55mg/d and
110mg/d phases; IS9 during 110mg/d phase) were excluded from the mean spot urine
concentration, the relationship between isoflavone intake and spot urine isoflavone
concentration is close to linear (Figure 21).
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Figure 21:
Mean isoflavone concentration in spot urine samples during each
supplement phase
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Figure 22:
Plasma concentration of isoflavones during each supplement phase
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The relationship between supplement dose and plasma isoflavone concentration is
close to linear.
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To further explore the relationship between increasing dose and the proportion of
ingested isoflavones absorbed and excreted, percentage recovery of the ingested dose
was plotted against oral intake in milligrams.
Percentage recovery in 24-hour urine samples was calculated using the equation
derived from Figure 13 to calculate urinary excretion in 24 hours from a given intake:
y = 6.63132x0.7421
where y = 24-hour urinary isoflavone excretion (ug/24h)
and x = isoflavone intake (ug/24h)
Percentage recovery was then defined as;
% recovery = 100(y ÷ x)
Similarly, plasma isoflavone concentration corresponding to a given intake was
calculated from the equation:
y = (3.3543x10-3)x0.4889
where y = plasma isoflavone in μg/ml
and x = isoflavone intake in μg/24h
and the percentage of the ingested dose appearing in plasma (per ml) was defined as;
% dose per ml plasma = 100(y ÷ x)
Percentage recovery for six values of x were calculated and plotted in Figures 23 and
24 which show a curvilinear relationship between ingested dose and percentage
recovery/percentage of the dose appearing in plasma.
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Figure 23:
Percentage of ingested dose recovered in 24-hour urines
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Figure 24:
Percentage of ingested dose per ml plasma
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EFFECT OF AGE ON THE RELATIONSHIPS BETWEEN INTAKE AND
EXCRETION AND PLASMA CONCENTRATION
No effect of the participant’s age on plasma concentration of isoflavones or urinary
isoflavone excretion over 24 hours was evident, as depicted in Figures 25 and 26.
Figure 25:
Relationship between participant's age and plasma isoflavone
concentration
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Figure 26:
Relationship between participant's age and 24h
urinary isoflavone excretion
R2 = 0.0029
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EFFECT OF GENDER ON THE RELATIONSHIP BETWEEN INTAKE AND
EXCRETION AND PLASMA CONCENTRATION
No significant difference in 24-hour urinary isoflavone excretion was found between
males and females over all phases of supplementation (p = 0.23). The relationship
between isoflavone intake and 24-hour urinary isoflavone excretion in the two groups
is shown in Figure 27.
Figure 27:
Relationship between isoflavone intake and excretion over
24hours in males and females
-20000
0
20000
40000
60000
80000
100000
120000
140000
160000
180000
0 50000 100000 150000 200000 250000
total isoflavone intake (ug/24h)
is
o
fl
av
o
n
e
ex
cr
et
io
n
(u
g
/2
4h
)
males
females
Linear (females)
Linear (males)
No difference was found in the relationship between isoflavone intake and plasma
isoflavone concentration between males and females (Figure 28).
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Figure 28:
Relationship between isoflavone intake and plasma isoflavone
concentration in males and females
-0.5
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
0 50000 100000 150000 200000 250000
isoflavone intake (ug/24h)
p
la
sm
a
is
o
fl
av
o
n
e
co
n
ce
n
tr
at
io
n
(u
g
/m
l)
males
females
Linear (females)
Linear (males)
Relationship between isoflavone intake a d plasma isoflavone conce tration in
males and females
Isoflavone intake (μg/24h)
Pl
as
m
a
is
of
la
vo
ne
co
nc
en
tr
at
io
n
(μ
g/
m
l)
Results
104
EFFECT OF BMI ON THE RELATIONSHIPS BETWEEN INTAKE AND
EXCRETION AND PLASMA CONCENTRATION
No effect of the participant’s BMI on plasma isoflavone concentration or on urinary
isoflavone excretion over 24 hours was evident, as depicted in Figures 29 and 30.
Figure 29:
Relationship between participant's BMI and plasma isoflavone
concentration
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Figure 30:
Relationship between participant's BMI and 24h urinary isoflavone
excretion
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DISCUSSION
24-hour urine, plasma and spot urine samples as biomarkers of isoflavone intake
Strong, statistically significant correlations were found between; a) isoflavone intake
and urinary isoflavone excretion over 24 hours; b) isoflavone intake and isoflavone
concentration in spot urine samples; c) isoflavone intake and plasma isoflavone
concentration.
No previous study has validated isoflavone biomarkers for this intake range.
Correlations observed in this study between intake and biomarkers were comparable
to or stronger than those reported by most other biomarker validation studies
discussed in Chapter 1 (Grace et al., 2004; Maskarinec et al., 1998; Ritchie et al.,
2004; Ritchie et al., 2004a; Ritchie et al., 2004b; Takashima et al., 2004; Verkasalo et
al., 2001).
This demonstrates that these markers are appropriate for use in intervention or
epidemiological studies as measures of isoflavone intake or compliance with
isoflavone supplementation. A further application might be in the relation of
isoflavone concentrations in in vitro studies to the human oral intake required to
achieve a similar circulating concentration.
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Agreement between the biomarkers
In this study, strong positive correlations were found between biomarkers of
isoflavone intake over the range of 0-165mg/d total isoflavones: 24hU isoflavones
with plasma isoflavones (r2 = 0.88), 24hU with spot urine samples (r2 = 0.84) and spot
urine with plasma samples (r2 = 0.83). This is comparable to or stronger than
correlations reported in other studies of isoflavone biomarkers, for example, in a
large population-based study (Grace et al. 2004) correlations (r2) between serum and
spot urine isoflavones were 0.74 before adjustment for urinary creatinine and 0.85
after creatinine adjustment.
Setchell et al. (2003a) also found highly significant though considerably less strong
correlations between biomarkers (maximum plasma concentrations of isoflavones
(Cmax) with urinary isoflavone concentration and total urinary output of isoflavones)
in a study of 13C3-labelled genistein and daidzein administered to 16 premenopausal
women. R2 values were as follows: between plasma daidzein Cmax and total urinary
daidzein 0.0558; between plasma genistein Cmax and total urinary genistein 0.4211;
between plasma daidzein Cmax and urinary daidzein concentration 0.085; and between
plasma genistein Cmax and urinary genistein concentration 0.286. Though the scatter
of points was wide, all correlations were highly significant.
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Outliers in spot urine isoflavone concentration
Isoflavone concentration in spot urine samples taken 5-7 hours after supplementation
correlated with isoflavone intake. However, outliers in spot urine concentration
skewed the mean spot urine isoflavone intake during 110mg/d supplementation to
produce an apparent plateau in urine concentration at high intakes that was not
evident with 24-hour urine collections. This effect disappeared when two outliers –
both noticeably dark urine samples - were excluded. For this reason, the relationship
between spot urine concentration and the volume of the 24-hour urine collection from
the previous 24 hours (as an approximation or surrogate measure of urine
concentration on the day of spot urine sampling) was examined.
However, no correlation was found between 24-hour urine volume and isoflavone
concentration in spot urine samples on the following day, even when outliers were
included (Figure 31).
Figure 31:
Relationship between spot urinary isoflavone concentration and
24-hour urine volume during 110mg/d supplementation
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One method of correcting for the concentration of spot urine samples when assessing
the excretion of a single metabolite is to measure creatinine concentration in the spot
urine sample. Urinary creatinine is then compared to the mean creatinine excretion
per day for an individual of the same age, gender and bodyweight and a correction
factor applied to the concentration of the metabolite of interest. This method has been
applied in some (Grace et al. 2004) but not all (Ritchie et al. 2004a) studies of urinary
isoflavones.
The results of this study indicate that even without creatinine adjustment, variation in
isoflavone concentration in spot urine samples is sufficiently related to isoflavone
intake to be used as a biomarker of intake. However, correcting for urinary creatinine
would be likely to produce a more robust biomarker and would avoid the need to
exclude very concentrated urine samples. Grace et al. (2004) corrected PE
concentration in spot urine samples for creatinine and found that this produced
stronger correlations with plasma PE concentrations. However, as discussed
previously, correlations between plasma and urinary isoflavones in this study were
robust by comparison with other published studies.
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Percentage urinary recovery
The relationship between isoflavone intake and urinary excretion over 24 hours
derived from the results of this study indicates that percentage recovery over 24 hours
will range from approximately 30% at intakes of 160mg/d to approximately 40% at
intakes of 25mg/d. There are a number of reasons why the ingested dose is not
completely recovered in 24-hour urine collections. Firstly, a small proportion of the
ingested dose is excreted in faeces, either without being absorbed or after hepatic
conjugation and biliary excretion (Adlercreutz & Mazur, 1997; Setchell et al., 2003b).
Secondly, some of the ingested isoflavones are metabolised to other compounds
before excretion. Genistein and daidzein may be metabolised to 3’7-
dihydroxyisoflavan, dihydrodaidzein, O-DMA, equol, methylequol and other
compounds (Adlercreutz & Mazur, 1997; Chang & Nair, 1995; Setchell et al., 2003b).
Thirdly, urinary excretion of isoflavones from a single dose is not complete within 24
hours but may also continue into the second and third day after ingestion (Setchell et
al., 2003a).
Bloedon et al. recovered 27-42% of ingested dose in urine during 24h after isoflavone
ingestion, using doses of 2, 4, 8 and 16mg/kg bodyweight.
Setchell et al. (2003a) recovered an average of 30% of 13C daidzein and 9% of 13C
genistein in urine over 24h. Most of the recovered isotopes were excreted in the first
24h after administration with a small proportion excreted on the second day and
excretion on the third and fourth days comparable to that before dosing. The
cumulative percentage recovery of genistein at 0.4mg/kg was 8.9% and at 0.8mg/kg
was 8.3%. For daidzein, cumulative percentage recovery at 0.4mg/kg was 34.5% and
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at 0.8mg/kg was 25.6%. However, no conclusions regarding the non-linearity of
relationship between dose and percentage recovery can be reached from two different
doses.
Limits of isoflavone uptake and excretion: the ‘plateau effect’
In this study, curvilinear relationships were demonstrated between isoflavone dose
and subsequent plasma isoflavone concentration and between isoflavone dose and
percentage urinary isoflavone recovery over 24 hours. This has not been previously
demonstrated although some data have suggested such a relationship (Setchell et al.
2003b).
Setchell et al. (2003a) reported that the bioavailability of genistein and daidzein did
not increase linearly between doses of 0.4 and 0.8mg/kg bodyweight (equivalent to
29.2 and 58.4mg/d for a 73kg person). Bioavailability as measured by AUCinf for
daidzein was 5.15 for the lower dose and 8.70 for the higher dose, while for genistein
it was 6.33 and 9.77, respectively.
Bloedon et al. (2002) noted some decrement in the percentage of the dose excreted in
24 hours at the higher doses they administered (doses were 2, 4, 8 and 16mg oral
isoflavones per kg bodyweight). Assuming a similar mean weight to participants in
the present study (73kg), this would equate to doses of 146, 292, 584 and 1168mg/d.
However, this same study reported a linear relationship (r2 > 0.92) between maximum
plasma concentrations of total genistein and total daidzein and between the area under
the plasma concentration-time curve (AUC) (r2>0.98) for total genistein and daidzein
Discussion
112
with increasing dose. They therefore propose that decrement in percentage urinary
recovery over 24 hours was due to the dose not being fully excreted within 24 hours.
Izumi et al. (2000) showed that very high plasma concentrations of isoflavones can be
attained after pharmacologic doses. Pharmacologic doses may override any rate-
limiting step, a common phenomenon that has previously been demonstrated for
vitamin E (Traber et al. 1998 cited in Setchell et al. 2003a).
The study by Bloedon et al. (2002) used two different isoflavone formulations, one
100% unconjugated and one 70% unconjugated, in contrast to the isoflavone
glycosides administered in this study and present in the soy nuts administered by
Setchell et al. (2003b). The mechanism of isoflavone absorption is not well
elucidated but since isoflavones are more slowly absorbed when conjugated to
glucose (Kano et al., 2006), it is reasonable to speculate that the rate of isoflavone
absorption might be limited at these larger doses, resulting in incomplete absorption
of the isoflavone dose from glycosides before normal intestinal transit has removed
the compounds from sites where they can be absorbed. Gut transit time is already
known to be a significant determinant of isoflavone bioavailability (Hendrich, 2002).
However, dose-response also tended towards curvilinearity in a study which used
three ascending doses of isolated, 13C3-labelled genistein and daidzein (Setchell et al.
2003b). Whether isoflavones are ingested with or without other foods may also be
significant.
Further studies of the relationship between isoflavone formulation and percentage
urinary recovery at increasing doses, or between isoflavone dose and faecal isoflavone
recovery, could address this question.
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If the proportion of the ingested dose absorbed is less for a larger dose, then studies or
therapeutic regimens designed to produce high plasma concentrations of isoflavones
would be more precise if supplements are administered in divided doses.
The effect of gender and body mass index
The effect of gender
No significant difference was found between the sexes in 24-hour urinary isoflavone
excretion or plasma isoflavone concentration during this study.
Published data on the effect of gender on isoflavone bioavailability and excretion are
contradictory. A 10-week soy feeding study in 76 healthy adults (Wiseman et al.,
2004) found no significant interaction of gender with plasma, urinary or faecal
isoflavone concentrations with the exception of significantly higher plasma O-DMA
concentrations in men than in women.
Bloedon et al. (2002) found significantly higher urinary excretion of total genistein
and daidzein over 24 hours in women than in men, but only when the isoflavone
formulation was 100% unconjugated, not when a 70% unconjugated formulation was
administered.
Faughnan et al. (2004) reported significantly higher urinary genistein recovery in
women after consumption of soy milk compared with textured vegetable protein,
while in men no difference in urinary genistein was detected between the different soy
foods. They did not find any effect of gender upon urinary daidzein excretion.
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Zhang et al. (1999) found that bioavailability of daidzein and genistein based on
plasma concentrations were similar in men and women although mean 48-hour
urinary excretion of these isoflavonoids was significantly different.
Lu and Anderson (1998) found that women initially excreted more isoflavones in
urine than men after soy milk supplementation, but that during the course of their 4-
week study a progressive decrease in urinary excretion of genistein and daidzein was
observed in women but not in men. This may explain the lack of any apparent gender
difference in the present study. Since each participant completed three or four weeks
of isoflavone supplementation (albeit separated by wash-out phases) and the order of
supplements was randomised, any tendency for women to excrete more isoflavones in
urine in response to supplementation might have been obscured by the duration of
supplementation. The same would apply to the study by Wiseman et al. (2004).
The effect of body mass index
If isoflavones, due to their lipophilicity, are able to accumulate in adipose tissue then
the ratio of lean to fatty tissue in an individual might affect the plasma concentrations
or rate of excretion of these compounds. Therefore, the relationship between
participants’ body mass index (BMI) and plasma concentrations and 24-hour urinary
excretion of isoflavones was tested. No correlation was found between BMI and
plasma isoflavone concentration or between BMI and 24-hour urinary isoflavone
excretion. The range of BMI among the study participants was 17.53-31.80 (mean
25.05), demonstrating that the biomarkers are valid over a wide range of body mass
index.
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Timing of spot urine and blood samples
Blood samples and spot urine samples were taken between 5 and 7 hours after
ingestion of the supplement. This time interval was chosen because the peak
concentration of isoflavones in plasma occurs at approximately 5-7 hours after
ingestion (Bloedon et al. 2002; Setchell et al. 2003a, 2003b).
The shape of plasma appearance and disappearance curves for isoflavones are
consistent within and between individuals and at different doses (Setchell et al.
2003a). Thus, provided that all participants were sampled at the same interval after
supplement ingestion a reasonably strong correlation would have been found between
intake and plasma concentration or excretion. However, the timing of samples after
isoflavone ingestion will profoundly affect the plasma concentration that is associated
with a particular intake.
When applying biomarkers in intervention studies where supplements are given once
daily, the equations derived from this study to relate intake to excretion up to
165mg/d can be most accurately applied if samples are taken 5-7 hours after
supplement ingestion. Divided doses of isoflavones throughout the day have been
less studied, but if three doses per day were taken and the plasma curves
superimposed then the diurnal variations in plasma and urine isoflavone
concentrations will be less great and the timing of blood and urine sampling becomes
less important. The ‘divided doses’ pattern of isoflavone ingestion is common when
isoflavone-rich foods are integrated into the habitual diet, and Grace et al. (2004)
validated untimed spot urine and plasma samples as biomarkers of low (<1.5mg/d)
dietary intakes of PE consumed as part of the habitual diet throughout the day.
Discussion
116
LIMITATIONS
Blinding:
No manufacturer could be found who would produce the three different potencies of
isoflavone supplement required for this study. While this range of doses is available
over-the-counter in a range of formulations, each individual manufacturer only
produces one potency. In order to keep the tablet formulation constant in each phase
of the study, the higher doses were achieved by giving two or three tablets at once.
This compromised the blinding of the study, as participants might easily have guessed
that taking more tablets equated to a higher dose phase. However, since
pharmacokinetic parameters not symptoms or subjective measures were used to assess
outcome, imperfect blinding was deemed to be less important than using supplements
with the same formulation for each phase.
Creatinine adjustment:
Given that the problems of correlating spot urine to blood are found in samples of
very concentrated urine (dark colour, small volume, unexpectedly high isoflavone
content), creatinine adjustment would have been likely to produce a more robust
correlation between intake and spot urine isoflavone concentration.
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Controlling extraneous variables
Isoflavone pharmacokinetics might have been affected by other components of
participants’ diets or other supplements and medications they consumed during the
study. In any study with free-living participants, compliance can only be monitored
by verbal checks, the timing of supplements and samples can be approximately but
not precisely controlled and there is no control over physical activity, diet and fluid
consumption. However, since this study was intended to provide a tool for clinical
and observational studies, the fact that such naturally-occurring variables were present
increases the generalisability of the work to other free-living human studies, even at
the expense of internal validity.
Interpretation of log-log graphs
Log-log graphs were used to clarify the relationship between intake and isoflavones in
biological fluids. A larger value of r2 (Pearson’s correlation coefficient) for the linear
regression lines on log-log graphs demonstrated that this model fitted the data better.
The same treatment of data has been applied in other studies of isoflavone biomarkers
(Arai et al., 2000; Atkinson et al., 2002; Frankenfeld et al., 2003; Frankenfeld et al.,
2002; Grace et al., 2004; Ritchie et al., 2004a; Ritchie et al., 2004b) and
pharmacokinetics (Setchell et al. 2003b).
However, examining the log-log graphs alone masks the spread of data points in the
original data set. For example, Figure 9 shows the relationship between isoflavone
intake and 24-hour urinary excretion. It can be seen from the graph that the spread of
data points becomes wider with increasing intake. When the data are transformed
using log10 (Figure 13), this spread of data at high intakes is no longer evident.
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Margins of error on log-log graphs of the relationship between isoflavone intake and
biomarkers appear small. For example, Figure 32 is a scatter plot of log10 isoflavone
intake against log10 isoflavone excretion in 24hour urines with the margins of error
encompassing the spread of data points shown in red. On this graph a y-axis error of
+/- 1 includes most of the outliers at all levels of intake.
Figure 32:
Errors in log 24h intake against log 24h excretion
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The equation of the upper error line is;
log10 intake = 0.7421(log1024hU excretion) + 1.8216
and the equation of the lower error line is;
log10 intake = 0.7421(log1024hU excretion) - 0.1784
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By computing these equations to give the relationship between intake and excretion,
as was performed for the equation of the linear regression on the scatter plot, it can be
determined that the equation of the upper error line relates to;
y = 66.31302x0.7421
and the equation of the lower error line relates to;
y = 1.507995x0.7421
Figure 33 shows these error margins derived from the graph of log(intake) against
log(24h urinary excretion) in terms of intake (μg/24h) and excretion (μg/24h). The
original data points before log transformation (in blue) and the relationship between
intake and 24h urinary excretion derived from Figure 13 (in yellow) are also plotted.
Figure 33 demonstrates the width of the possible errors incurred by using an equation
derived from a log-log graph to predict intake from excretion (or vice versa) and
demonstrates the increased potential for error at higher intakes that is incurred by
using this model.
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Figure 33:
Errors translated from log-log graph to original
scatter plot
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The above exercise also explains the spread of data points observed on the original
scatter plot of intake (μg/24h) against excretion (μg/24h) (Figure 9) and justifies using
logarithms of both axes to confirm the relationship between the two variables. This
exercise illustrates why the relationships between isoflavone intake and biomarkers
must be interpreted with caution.
Errors translated from log-log graph to original scatter plot
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CONCLUSIONS
The aims of this study were to validate 24-hour urine, timed plasma and timed spot
urine samples as reliable measures of isoflavones intakes up to 165mg/d and to
determine whether plasma concentration or urinary excretion reaches a plateau at this
level of intake.
From the results presented it can be concluded that all the above biomarkers are valid
for this intake range and can be applied in epidemiological or intervention studies as
measures of isoflavone intake or compliance with isoflavone supplementation. A
further application might be in assisting extrapolation of in vitro findings to
corresponding human intakes based upon the concentration at which effects are
manifest in vitro.
A curvilinear relationship was defined between a) isoflavone dose and bioavailability
in plasma and b) isoflavone dose and urinary excretion over 24 hours.
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Appendix 1: Isoflavones and their glycosides. (Reproduced from COT 2003b)
Appendix
140
Appendix 2: Structural similarity of PE to oestradiol
(reproduced from COT 2003b)
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Appendix 3: Disparity in serum concentration between PE and oestradiol
(reproduced from Setchell 1998)
Oestradiol is shown as unfilled boxes ( ), isoflavones as black boxes ( ). Data
are shown on a log scale.
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Appendix 4: Isoflavone Tablet Specification
Manufacturer: Custom Pharmaceuticals
Supplied by: Lamberts Healthcare Ltd
Tablet Physical Properties
Shape
Ovaloid
Mean Weight 1030mg
Colour
White
Quantity per carton 30 Tablets
FORMULATION
Tablet Content Quantity Per Tablet Unit
RM/12/031 Microcrystalline Cellulose 428.000 mg
RM/13/022 Soya Isoflavone Extract (40%) Glycine max 250.000 mg
RM/03/191 Calcium Carbonate 210.000 mg
RM/15/169 Pregelatinised Maize Starch 71.000 mg
RM/01/002 Croscarmellose Sodium 30.000 mg
RM/18/041 Stearic Acid Vegetable 15.000 mg
RM/12/011 Magnesium Stearate 5.000 mg
RM/01/007 Silicon Dioxide Colloidal 1.000 mg
CORE WEIGHT 1010.000 mg
Coating
RM/12/039 Hypromellose 5cps 17.450 mg
(RM/12/150) Mastercote White FA0961G solids 10.100 mg
RM/07/008 Glycerol Vegetable 2.760 mg
COATING WEIGHT 30.31 mg
TABLET WEIGHT 1040.310 mg
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FINISHED PRODUCT SPECIFICATION
Tablet Appearance
White, ovaloid, film coated tablet
Odour Little or none
Uniformity of Weight Complies with EP Specification
Average Weight (cores) 1010mg (limits 990 – 1030mg)
Average Weight (coated) 1030mg (limits 1000 – 1060mg)
Length (cores)
19.6mm (limits 19.0 – 20.2mm)
Width (cores)
8.45mm (limits 8.2 – 8.7mm)
Thickness (cores)
7.2mm (limits 7.0 – 7.4mm)
Hardness (cores)
Not less than 20kp
Friability (cores)
Not more than 0.3%
Disintegration (cores)
Not more than 30 minutes
Disintegration (coated)
Not more than 60 minutes
NOTE
1. Soya Isoflavone Extract (40%) – Genistin 48mg, Glycitein 5mg, Daidzin 41mg
A Certificate of analysis should be supplied with each batch.
This specification should be read in conjunction with our general purchasing conditions for
tablets, and supercedes all previous issues.
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Appendix 4: Placebo Tablet Specification
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Appendix 5: Recruitment poster
We are looking to recruit healthy men and women to take part in
a study of compounds in the food which you eat regularly and in
a nutritional supplement made from soya beans.
We wish to measure the levels of certain plant compounds in
your urine and blood and see how this changes when you take a
supplement.
The study will involve three weeks of supplementation and we
will ask you for blood and urine samples twice during each of
these periods.
For more information and to volunteer
please contact:
Dr Margaret Ritchie
Research and Teaching Fellow
Cancer Biology Group
Bute Medical School
Tel 01334 463 534
Miss Jay Mackinnon, ljm62@st-andrews.ac.uk
PhD student
Cancer Biology Group
Bute Medical School
Tel 01334 463 534
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Appendix 6: Pre-enrolment telephone interview schedule
Comparison of Plasma and Urine Concentrations of Phyto-oestrogens Following
Dietary Isoflavone Supplementation
PROCEDURE FOR THE INITIAL TELEPHONE SCREENING OF VOLUNTEERS
Time _________________
Date __________________
1. Thank-you for telephoning
2. Where did you hear about the study?
___________________________________
3. First of all, can I ask you a few questions just to see if the study is suitable for
you, and then, if it appears that it is, we can arrange an appointment with
myself so that you can discuss the details with me and find out if you wish to
take part in the study. I will post out a volunteer information sheet to you
which you may read over before you come for your appointment.
4. Full name
________________________________________________________
5. Age _____________ Date of Birth __________________
6. Contact phone number (home) __________________________________
(work) __________________________________
7. What is your home address?
Postcode:
8. Sex: male / female
9. Smoking habits? Current smoker / ex-smoker / non-smoker
10. Do you have any health problems?
Yes / No
11. Are you currently taking any medication?
_______________________________________________________________
_______________________________________________________________
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12. Have you taken any antibiotics within the last six weeks?
Yes / No
13. Do you take any dietary supplements?
Yes / No
14. If yes, what are they?
_______________________________________________________________
_______________________________________________________________
15. What is the name and address of your GP?
16. Are you resident within the St Andrews area and able to participate within the
next two to six weeks?
Yes / No
17. We will be asking for blood samples, urine samples, and 24-hour urine
collections. Are you willing to do this?
Yes / No
18. You will also be asked to complete food diaries. Are you willing to do this?
Yes / No
19. Are you currently participating in any other research study?
Yes / No
20. Are you currently in employment? (question asked for scheduling purposes)
Full time _______
Part time _______
Not employed _______
If no points which indicate that the trial is unsuitable for the volunteer, then proceed
to arrange an appointment, preferably within the next two to six weeks.
Appointment should be booked and the time recorded in the study diary. Interview
times are between 10.30am and 1.30pm on Monday, Wednesday, Thursday and
Friday. Three people can be booked into one appointment time and the appointment
should last for about 20 minutes.
Emphasise that an appointment does not mean commitment to the study, it provides
an opportunity to get more information so that they can make up their minds after
they have a chance to ask questions and discuss it in detail.
Send out an appointment card and letter with the volunteer information sheets and
directions to the Bute Medical Building.
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Appendix 7: Participant information sheet
Information for Participants
Comparison of Plasma and Urine Concentrations of Phyto-oestrogens Following
Dietary Isoflavone Supplementation.
We invite you to take part in a research project. We believe it to be of potential
importance. However, before you decide whether or not you wish to participate, we
need to be sure that you understand firstly why you are doing it, and secondly, what it
would involve if you agreed. We are therefore providing you with the following
information. Read it carefully and be sure to ask any questions you have. We will do
our best to explain and to provide any information you may ask for now or later.
Reason for the study
Foods contain a number of different nutrients such as fats, carbohydrates, vitamins,
minerals and other substances. Some of these substances are called plant oestrogens.
Plant oestrogens such as isoflavones are naturally occurring chemicals in soya beans
and other foods. There have been a number of studies investigating their role in the
prevention of several diseases such as cancer or heart disease. In order to assess the
amounts of these compounds in your diet, we measure them in blood and urine.
This study aims to find several important pieces of information: how much of these
plant oestrogens is present in your blood after you eat them and how much is excreted
in your urine. This information could lead to a better understanding of what happens
to these compounds in the body and help us to provide better nutritional advice in the
future.
What the study will involve
We would like to ask healthy volunteers to help with a study which will last for six
weeks, and will measure the levels of plant oestrogens in blood and urine samples
when you are taking a supplement and when you are not.
If you agree to take part in the study, you will be asked to read and sign the local
Ethics Committee standard consent form.
At the initial interview and discussion appointment you will be given a food diary to
fill in for 7 days. You will also be given a measuring jug and urine container so that
you can collect all the urine you pass over a 24-hour period, and tablets to take during
this collection period which will allow us to check whether your urine collection is
complete.
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Visit 1:
We will collect your 24-hour urine sample and food diary from you, and you will be
asked to provide another small urine sample and a small blood sample (10ml, which is
about 2 teaspoonfuls). We will use these to measure the amount of isoflavones which
are present before you supplement your diet.
You will be provided with 7 days supply of the supplement, which you should take at
the same time each day. The time of day will depend on when you can visit us, and
we will agree this together.
Interval Visits:
You will be asked to attend interval visits three days after Visit 1, ten days after Visit
2 and ten days after Visit 3, just to provide a small urine sample and blood sample and
to tell us about the foods you have eaten over the previous 24 hours. This allows us to
see how the foods you eat are having an effect on the plant oestrogens in your blood
and urine.
Visit 2, Visit 3 and Visit 4:
Visit 2 will be one week after Visit 1, Visit 3 will be two weeks after Visit 2 and Visit
4 will be two weeks after Visit 3.
The day before each visit, we would like you to collect all the urine you pass over a
24 hour period and to take tablets as you did the first time you made a 24-hour urine
collection, to allow us to make sure it is complete. On this day and on the day of your
visit, we would also like you to keep a record of all that you eat and drink.
We will collect your dietary record and your 24-hour urine collection from you at the
visit, and take another small blood sample and small urine sample. We will give you
another 7 days supply of supplements, which you should begin to take one week after
your visit. For the week following each study visit you will not need to take any
supplements.
Visit 4 will be your last visit, so you will not be given any more supplements at this
visit.
Finding out the study’s results
Results will be published in scientific journals. We will send you a brief summary
when the final results of the study are available. If you would like to receive them,
we will also send you a summary of your own nutrient intakes estimated from your
food diaries.
All the information you give us will be treated as confidential and used solely for the
purposes of the research study. Individual participants will not be identifiable in any
report about the study.
You are under no obligation to take part in this study. If you do decide to take part,
you are free to withdraw at any time without giving a reason and without it affecting
your future medical care. Please feel free to ask any questions you may have about
the study (the contact number is below)
Dr Margaret R. Ritchie 01334 463 534
Research Fellow and Teaching Fellow
Bute Medical School, University of St Andrews
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Appendix 8: Consent form (printed on Bute Medical School letterhead)
Comparison of Plasma and Urine Concentrations of Phyto-oestrogens Following
Dietary Isoflavone Supplementation
Consent Form
The volunteer should complete this form herself/himself
Please circle
as appropriate
Have you read the volunteer information sheet? Yes / No
Have you received enough information about the study? Yes / No
Have you had the opportunity to ask questions and discuss the study? Yes / No
Have you received satisfactory answers to all of your questions? Yes / No
Who have you spoken to? ……………………………………….............
Do you understand that you are free to withdraw from the study;
At any time? Yes / No
Without having to give a reason? Yes / No
Without this affecting your future medical care? Yes / No
Do you agree to take part in this study? Yes / No
Volunteer’s signature………………………………………………. Date……………
Name (please print)……………………………………………………………………..
Contact telephone numbers:
Home……………………………..…… Mobile…………………………………..
Email address: ……………………………………………………………..
Researcher’s signature……………………………………………… Date…………...
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Appendix 9: Letter to general practitioners
[printed on Bute Medical School letterhead]
West Burn Lane
St Andrews
KY16 9TS
[date]
[practice address]
Dear Doctors,
Re: [participant name and address]
DOB:
Your patient, [name], has agreed to participate in a study investigating the relationship
between soy isoflavone supplementation, concentrations of isoflavones in plasma and
isoflavone excretion in urine.
S/he will be asked to complete a diet diary and to provide urine and blood samples,
and will be randomised to receive isoflavone tablets containing 50mg or 100mg of
isoflavones or placebo in a crossover design, as detailed in the enclosed information
sheet.
If you have any questions about this study or feel, for any reason, that your patient
should not take part, please contact Dr Margaret Ritchie at the Bute Medical School,
University of St Andrews, tel. 01334 463 534, email mrr3@st-andrews.ac.uk
Yours sincerely,
Dr Margaret R. Ritchie
Research Fellow and Teaching Fellow
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Appendix 10: Dietary recording instructions
Cancer Biology Group, Bute Medical School, University of St Andrews, KY16 9TS
Comparison of Plasma and Urine Concentrations of
Phyto-oestrogens Following Dietary Isoflavone
Supplementation
FOOD RECORD BOOK
7-DAY RECORD
Name:_____________________________
*Please bring this Record with you
when you attend the Study Visit
at The Bute Medical School, University of St Andrews.
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Instructions for recording your food and drink
Amount/portion. Describe each item in spoonfuls, or other household
measures, or as small, medium or large portions
Breads and Rolls:
Description Give type of bread or rolls (white, brown, wholemeal etc.).
Size of portion. Record the number of slices of bread and whether thick, average or
thin sliced. For rolls record size. Note size of left over portion.
Fat Spreads
Description Give type of fat spread (Olivio, Tesco Low-fat spread, Flora,
Flora-light, Flora-Extra Rich, Safeways sunflower etc), or state `unknown'.
If spreading on bread/rolls record whether thin, thick or average
Size of portion. Record the amount (1 curl or 1 teaspoon) added to
potatoes/vegetables or used in frying etc. Record the amount of any left over portion.
Cooking Fats and Oils
Description Type and brand (hard vegetable oil, lard, Tesco vegetable oil, Soya,
Sunflower or Olive oil etc.).
Amount of oil used i.e. number of tablespoons or teaspoons. If used for frying, state
whether shallow or deep frying.
Sandwich or Roll Fillings
Description Give as complete details as possible: cheese, ham, beef, tuna etc.
+ salad, mayonnaise, pickles. (NB remember type of bread). Portion size of each
individual item in the sandwich , if possible.
Record the amount of any uneaten portion.
Milk: On Cereals, in Hot Drinks, in Cold Drinks, used in home cooking
Description Give type (full, half or low fat, condensed, dried skimmed etc.).
Amount of milk used e.g. glassful, cupful, tablespoons.
Record the amount of any left over portion
Meat and Fish
Description Give type (and cut of meat), and method of cooking, and if +skin and
fat eaten. Remember details of fat/oils used
Size of portion. Record amount of any uneaten portion.
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Vegetables
Description Give type, whether fresh or tinned, and the method of cooking, or if
eaten raw. Remember details of fat/oils used
Size of portion. Record amount of any uneaten portion. (of each vegetable).
Fruits
Description Give type, if raw, tinned or cooked, and whether skin eaten.
Size of portion. Record amount of any uneaten portion.
Home-Cooked Dishes
Description Give name of dish and main ingredients used. Remember details of
fat/oils used. Record amount of each ingredient used and the method of cooking.
Record the amount/size of the portion taken. Record the amount of any uneaten
portion.
Ready-prepared/Bought Dishes
Description Give the full information provided on the packet (or stick ingredients
and nutrition label into food record book).
Size of portion. Give the size/amount of the portion taken. Record the amount of any
uneaten food
Eating Out
Description Describe all food items as fully as possible, and method of cooking if
known. Give type of shop/restaurant (chip shop, indian etc).
Amount/portion. Describe each item in spoonfuls, or other household measures, or as
small, medium or large portions. Record the amount of any uneaten food
Cereals, Biscuits, Sweets and all other Foods
Description: Give Brand Name and type in as much detail as possible.
Size of portion. Record the amount of any uneaten portion.
Non-alcoholic Drinks
Description: Give type, and additions of milk, sugar etc. to hot drinks. Say whether
squash, fizzy, diet or natural fruit juices.
Size of portion e.g. average glass, carton, tumbler, wine glass etc.
Record the amount of any portion which is not drunk.
Alcoholic Drinks
Description Give type (heavy, lager, red/white wine, whisky etc.) and mixers.
Amount / portion e.g. pint, half pint, bottle, small can, large can or record as single
pub measures.
Appendix
155
Foods for which you regularly use only 1 type and
brand
If, for example, you always use semi-skimmed milk at home, or always cook
with a blended vegetable oil, you may give these details below, to avoid
repeating the information each time you eat it.
Type of milk ALWAYS
used:_________________________________________
Type of fat spread ALWAYS
used:_____________________________________
Type of ________________________ALWAYS
used:_____________________
Type of ________________________ALWAYS
used:_____________________
Type of ________________________ALWAYS
used:_____________________
Please remember that if you change from your usual type half way through
completing your Food Record, or eat differently when away from home,
you must give the details in the record.
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Appendix 11: 24-hour urine collection instructions
Comparison of Plasma and Urine Concentrations of Phyto-oestrogens Following
Dietary Isoflavone Supplementation
24-HOUR URINE COLLECTION INSTRUCTION SHEET
Name __________________________________________ ID no. _______________
Tel no (home) ___________________________________________
(work)___________________________________________
Date of start: day _________________ date ___________________
When you get up on __________________________ (day), DISCARD your first
urine specimen. Please fill in the time you did this
___________________________________________
From then on put every specimen (every drop!) into the bottles provided.
Please remember to take PABA tablets with breakfast, lunch and dinner and note the
time
Breakfast ___________________________________
Lunch ___________________________________
Dinner ___________________________________
Please note: it is very important that you take
the last PABA tablet before 8pm
Put your last specimen in the bottles at about the same time as you did on the previous
morning (at the start of the collection). Please fill in the day, date and time below.
Day ________________ Date ______________ Time __________________
Please remember to pass urine before passing a stool, otherwise you may lose some
urine.
Did you lose any specimens?
________________________________________________
Did you have any problems?
________________________________________________
Please return urine collections to __________________________________________
on _____________________________________________
Thank-you for your co-operation. If there are any problems with this collection, may
we ask you to repeat it?
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Appendix 12: Invalid 24-hour urine collections:
Participant ID Supplement phase % PABA recovery
IS 23 Baseline 73
IS 23 55mg/d 20
IS 48 Baseline 78
IS 48 110mg/d 38
IS 63 Baseline 5
IS 63 Placebo 80
IS 63 55mg/d 82
IS 26 110mg/d 72
IS 26 55mg/d 34
IS 26 165mg/d 40
IS 6 110mg/d 77
IS 17 110mg/d 34
IS 24 55mg/d 70
IS 1 165mg/d 56
IS 5 165mg/d 66
IS 61 55mg/d 84
IS 66 Placebo 80
